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Abstract 
Many common neurological disorders like traumatic brain injury (TBI) or stroke cause a 
loss of functional neurons and trigger a comprehensive response of glial cells, called 
reactive gliosis. Since reactive gliosis produces a persisting glial scar and since 
neurogenesis in the adult mammalian brain is insufficient to replace lost neurons, these 
conditions often compromise cerebral functions and lead to permanent disability with 
enormous socioeconomic burdens.  
In the adult zebrafish brain, however, ventricular ependymoglia responds to brain 
injuries with increased generation of new neurons, which are recruited to the injury site. 
A key mechanism regulating differentiation and proliferation of neuronal precursors in 
zebrafish is the aryl hydrocarbon receptor (AhR) pathway. In other organs like the 
hematopoietic system, AhR is well known to control essential biological functions 
including stress response and maintenance, proliferation and differentiation of stem 
cells. 
As reactive astrocytes, one of the main actors in reactive gliosis, show features of neural 
stem cells, the aim of my thesis was to examine whether AhR signalling plays a role in 
reactive gliosis as well and to what capacity AhR activation affects the response to TBIs 
in the mammalian brain. To address this question, I looked at AhR expression in the 
intact and the injured mouse brain and analysed the effects of AhR activation in the 
injured cerebral cortex at cellular and molecular levels. For this, I used 
bromodeoxyuridine (BrdU) incorporation to examine proliferation of different glial cells 
in vivo, proteome analysis and the neurosphere assay, an in vitro tool to assesses the key 
features of neural stem cells: proliferation, self-renewal, and multipotency. 
In the intact brain, AhR was only detectable in the dentate gyrus of the hippocampus, 
which is known for its high neurogenic activity. Following brain injuries, however, AhR 
was also expressed in reactive astrocytes around the injury site and AhR activation 
significantly altered proliferation of reactive astrocytes in vivo. Oral application of an 
AhR agonist additionally enhanced stem cell properties of reactive astrocytes in vitro. It 
increased sphere formation of cells isolated from the injured cerebral cortex without 
limiting their self-renewing capacity or neurogenic potential. In brain regions where 
AhR is not expressed, treatment with an AhR agonist did not increase sphere formation. 
Proteome analysis confirmed the effects observed in vivo and in vitro and gave 
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important hints about the mechanisms by which AhR signalling might induce changes in 
proliferation and in the potential of reactive astrocytes.  
These findings suggest AhR signalling as modulating factor in reactive gliosis and as key 
player in the mediation of stem cell properties in reactive astrocytes. It provides an 
interesting target for the reactivation of neurogenesis after brain damage and should 
therefore be subject of further research in order to aid the development of novel 
therapeutic strategies for all neurological conditions associated with a loss of functional 
neurons.  
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Zusammenfassung 
 
Zahlreiche neurologische Erkrankungen, beispielsweise Schädel-Hirn-Traumata und 
Schlaganfälle, gehen mit dem Verlust von Neuronen einher und bewirken eine 
umfassende Reaktion glialer Zellen. Diese „reaktive Gliose“ führt bei Säugetieren zur 
Ausbildung einer permanenten Glianarbe. Aus diesem Grund und da untergegangene 
Nervenzellen im adulten Gehirn nicht durch die auf wenige Stammzellnischen begrenzte 
Neurogenese ersetzt werden können, gehen diese Erkrankungen beim Menschen häufig 
mit einer dauerhaften Behinderung sowie weitreichenden sozioökonomischen 
Belastungen einher.  
Beim Zebrafisch hingegen bewirkt eine Verletzung des Gehirns, anders als bei 
Säugetieren, die vermehrte Bildung neuer Neurone durch ventrikuläre Ependymzellen 
im Telencephalon, welche an den Ort der Verletzung rekrutiert werden. Ein 
Schlüsselmechanismus bei der Regulation von Differenzierung und Proliferation der 
neuronalen Vorläuferzellen im Zebrafisch ist der Aryl-Hydrocarbon-Rezeptor(AhR)-
Signalweg. In anderen Organsystemen wie dem hämatopoetischen System kontrolliert 
der AhR-Signalweg ebenfalls essentielle biologische Funktionen einschließlich der 
Erhaltung, Proliferation und Differenzierung von Stammzellen.  
Auch reaktive Astrozyten, wichtige Mediatoren der reaktiven Gliose, weisen einige 
Merkmale neuronaler Stammzellen auf. Diese Arbeit widmet sich daher der Frage, ob 
der AhR-Signalweg auch in der reaktiven Gliose eine Rolle spielt und inwiefern die 
Aktivierung des AhR im Mausmodell die Reaktion auf Verletzungen des zerebralen 
Kortex beeinflusst. Hierzu untersuchte ich zunächst immunhistochemisch das 
Expressionsmuster des AhR im intakten und im verletzten Gehirn der Maus und 
analysierte die Effekte der AhR-Aktivierung im verletzten Großhirnkortex auf zellulärer 
und molekularer Ebene. Die systemische Gabe von Bromodeoxyuridin (BrdU), welches 
sich in neu synthetisierte DNA einlagert, erlaubte dabei die Bestimmung der 
Proliferationsraten einzelner Gliazellen in vivo und mit dem Neurosphären-Assay 
konnten die wichtigsten Stammzelleigenschaften in vitro erhoben werden: Proliferation, 
Selbsterneuerung und Multipotenz. Ergänzend wurde eine Proteomanalyse 
durchgeführt. 
Im intakten Gehirn konnte der AhR lediglich im Gyrus dentatus des Hippocampus, einer 
Region mit bekannt hoher neurogener Aktivität, nachgewiesen werden. Nach Verletzung 
des Kortex exprimieren jedoch auch benachbarte Astrozyten den AhR und die 
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Aktivierung des AhR änderte die Proliferationsrate reaktiver Astrozyten in vivo 
signifikant. Zudem förderte die orale Gabe eines AhR-Agonisten die Ausbildung von 
Stammzelleigenschaften reaktiver Astrozyten in vitro: Zellen, die aus der verletzten 
Kortexregion isoliert wurden, bildeten vermehrt Neurosphären ohne Einbußen ihres 
neurogenen Potentials und der Fähigkeit zur Selbsterneuerung. In Gehirnregionen ohne 
AhR-Expression änderte sich die Anzahl der Neurosphären nach Gabe eines AhR-
Agonisten hingegen nicht. Proteomanalysen unterstützten die Beobachtungen in vivo 
und lieferten wichtige Hinweise zu den Mechanismen, mit denen der AhR-Signalweg 
Änderungen der Proliferation und des Stammzellpotentials reaktiver Astrozyten 
induziert. 
Die im Rahmen dieser Arbeit erhobenen Daten legen den AhR-Signalweg als 
modulierenden Faktor der reaktiven Gliose und möglichen Schlüsselmechanismus in der 
Vermittlung von Stammzelleigenschaften reaktiver Astrozyten nahe. Dies macht den 
AhR zu einem vielversprechenden Ansatzpunkt bei der Suche nach neuen 
therapeutischen Strategien für alle neurologischen Erkrankungen, die mit einem Verlust 
von Neuronen assoziiert sind. Deshalb sollte der AhR auch zukünftig Gegenstand der 
Forschung auf diesem Gebiet sein.  
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1 Introduction 
1.1 Relevance of traumatic brain injuries 
According to the World Health Organization (WHO), traumatic brain injuries (TBI) are 
one of the major causes of death and permanent disability worldwide. TBI account for 
more years of disability than any other disease since children and young adults are 
especially exposed to risk factors for TBI, i.e. motor vehicle traffic, sports, construction 
and violence (Faul, Xu, Wald, & Coronado, 2010). For Europe, an annual incidence of 235 
cases per 100,000 inhabitants is estimated (WorldHealthOrganization, 2006). 
TBI do not only affect patients, but also society as a whole. In Europe alone, TBIs cause 
enormous socioeconomic costs of approximately 33 billion Euros per year. Direct and 
especially indirect health costs due to loss of productivity are a huge burden for every 
economy, above all in developing countries, where TBIs are much more frequent than in 
Europe.  
The WHO and national governments countered the social and economic relevance of 
TBIs with prevention measures. By means of seat belts, child safety seats, speed limits 
and stricter occupational safety regulations, the incidence of TBIs declines in 
industrialized countries. Due to medical advances, the lethality of TBI also dropped for 
about three-quarters from the 1970s to the beginning of the 21st century. But at the 
same time, the number of people living with disabilities resulting from TBI increased 
concomitantly. Treatment of TBI is still restricted to maintenance of vital functions, 
avoidance of secondary brain damage and compensation of resulting disabilities. 
Current guidelines focus on measures to ensure sufficient oxygen supply to the brain 
and to avoid a critical increase in intracranial pressure (Firsching et al., 2015). These 
therapies merely limit consequential damage due to hypoxia or elevated intracranial 
pressure, but none of them are capable of reversing neuronal damage and the 
complications thereof.  
In contrast to humans and other mammals, whose brains and spinal cords do not 
regenerate, other species like zebrafish have remarkable regenerative capacities. 
Neurogenesis in the ventricular zone of the zebrafish telencephalon increases in 
response to brain injuries and provides new neurons that are recruited to the 
parenchyma and replace the lost ones. Therefore, the adult zebrafish telencephalon 
might provide a useful model for understanding the mechanisms required for neuronal 
regeneration, which is the basis for the development of causal therapies for TBI and 
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other disease conditions that are associated with a loss of functional neurons like stroke 
and neurodegenerative diseases. 
1.2 Response to traumatic brain injuries 
Traumatic brain injuries (TBIs) always lead to a loss of functional brain parenchyma due 
to primary and/or secondary brain damage. Primary brain damage results from direct 
mechanical forces that take effect right at the moment of injury and is therefore 
inaccessible to medical therapies. Secondary brain damage, however, is the focus of 
acute medical care. It evolves gradually over the first hours to days after injury and 
results from an entire array of changes in the central nervous system (CNS) 
homeostasis. Complications such as ischemia, hypoxia, cerebral oedema, inflammation, 
leakage of the blood-brain barrier (BBB) and excitotoxicity of neurotransmitters further 
damage vital brain tissue and thereby determine the extent of secondary brain damage.  
Apart from the initial trauma severity, the extent of the secondary brain damage also 
depends critically on how effective wound healing is able to restore CNS integrity and 
homeostasis. The process of wound healing can be divided into three distinct phases: 
Cell death and inflammation, cell replacement and tissue remodelling (Burda & 
Sofroniew, 2014) (Figure 1.1).  
The first, acute phase is dominated by cell death and the initiation of an inflammatory 
response. Following cerebral trauma, the blood-brain-barrier (BBB) breaks down and 
plasma proteins, electrolytes, platelets and immune cells, which are normally excluded 
from the central nervous system, penetrate the brain parenchyma and disrupt the 
chemical and ionic environment (Obermeier, Daneman, & Ransohoff, 2013). At the same 
time, the release of danger associated molecular patterns (DAMPs) by damaged glial 
cells and neurons evokes an inflammatory reaction at the site of injury. This 
inflammation reinforces the invasion of immune cells by expressing leucocyte adhesion 
molecules (Icam1, Vcam1, E- and P-selectines) on endothelial cells (Daneman, 2012). It 
also initiates phagocytic clearance of cell debris by microglia and macrophages and 
reactivates glial cells (Zhang et al., 2010).  
The reactivation of glial cells and other local cells like pericytes and endothelial 
progenitors introduces the phase of tissue replacement, which is crucial to restore the 
BBB and to limit the spread of damage. Microglia and NG2-glia respond early to brain 
insults, migrate towards the injury site and increase proliferation (Simon, Gotz, & 
Dimou, 2011; Stence, Waite, & Dailey, 2001). Astrocytes on the contrary do not migrate 
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and proliferation is delayed (Bardehle et al., 2013). The proliferation of glial cells, above 
all astrocytes, creates a boarder that protects surrounding functional neural tissue from 
inflammatory and cytotoxic factors in the immediate lesion core and the proliferation of 
endothelial progenitors, fibroblasts and pericytes helps to replace damaged blood 
vessels. 
About 7 days after injury, in the phase of tissue remodelling, the formerly beneficial 
astrocytic boarder transforms into a persisting astrocytic scar, which is regarded to be 
the main inhibitor of axonal regeneration in the CNS. This transformation illustrates, 
that the beneficial effects of reactive gliosis in the fist days after injury impede functional 
recovery afterwards (Reviewed in (Pekny & Pekna, 2016). For this reason, finding ways 
to specifically block the detrimental effects of scar formation without diminishing the 
beneficial effects is one of the major challenges of current research in this field.  
 
Figure 1.1 
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Figure 1.1 Phases and Time Course of Multicellular Responses to Acute Focal CNS Damage 
During periods of cell death (A), cell replacement (B), and tissue remodelling (C), numerous overlapping 
events occur (D) that involve interactions among CNS intrinsic neural cells, CNS intrinsic non-neuronal 
cells, and cells infiltrating from the circulation. Based on Burda and Sofroniew (2014) 
 
1.3 Glial cells and their role in reactive gliosis 
1.3.1 NG2 glia 
NG2 glia came into focus for neuroscientists, since they are the only CNS intrinsic cells 
that proliferate outside the neurogenic niches (Dimou, Simon, Kirchhoff, Takebayashi, & 
Gotz, 2008) and possess the remarkable ability to self renew throughout a lifetime 
(Hughes, Kang, Fukaya, & Bergles, 2013). NG2 glia gives rise to cells of the 
oligodendrocytic lineage, but also to a low number of astrocytes during development 
(Zhu, Bergles, & Nishiyama, 2008; Zhu et al., 2011) and researchers have even described 
an in-vitro fate switch into neurons (Kondo & Raff, 2000). Due to these hints of 
multipotency, the long cell cycle length and their self-renewal capacity, stem cell-like 
properties of NG2 glia have been discussed (Richardson, Young, Tripathi, & McKenzie, 
2011).  
In the healthy cortical gray matter of three months old mice, 80% of all NG2 glia 
proliferate with a long cell cycle length of approximately 37 days (Simon et al., 2011). 
After injury, however, their proliferation rate bursts, they become hypertrophic, 
upregulate NG2, polarize and migrate towards the lesion site (Simon et al., 2011; Tan, 
Zhang, & Levine, 2005). This behaviour strongly implies a role of NG2 glia in wound 
healing and scar formation after traumatic brain injuries, although their impact is not 
yet fully understood. In NG2-knockout mice, traumatic brain injuries lead to enhanced 
numbers and a fulminant reaction of activated Iba-1+/CD45+ microglia/macrophages 
and infiltrating CD45+ leukocytes as well as increased neurotoxicity and a worse 
neurological outcome (Huang et al., 2016). On the other hand, NG2 glia have also proven 
to be inhibitory for axonal regrowth after CNS damage (reviewed in Tan et al. (2005)).  
1.3.2 Microglia 
The function of microglia is intensively studied. Microglia account for approximately 
10% of all cells in the adult brain (Lawson, Perry, Dri, & Gordon, 1990) and with 
functions similar to peripheral macrophages, they are the major operators of active 
immune defence in the central nervous system. They monitor their environment with 
highly ramified and motile processes and phagocyte accumulated metabolites and tissue 
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debris (Nimmerjahn, Kirchhoff, & Helmchen, 2005). Under physiological conditions, the 
immunosuppressive environment of the CNS keeps microglia in this surveying state. 
This downregulation of immune response is, among other factors, mediated by microgial 
surface receptors for CD200 (OX2), which are expressed on neurons, and CXCCL1 
(Fractalkine), released by neurons and astrocytes (Kettenmann, Hanisch, Noda, & 
Verkhratsky, 2011). Loss of these factors and all kinds of homeostatic disturbances shift 
the activity state of microglia from a resting to a reactive state. Potent activators of 
microglia, including cytokines, chemokines, DAMPs that were released from damaged 
cells, plasma proteins and proteins that are present in critical concentrations or in 
abnormal structures, are listed in Table 1.1.  
Within minutes after injury, microglia transform into hypertrophic, mobile phagocytes 
with amoeboid morphology (Nimmerjahn et al., 2005), commence proliferation, polarize 
and migrate towards the injury site (Davalos et al., 2005). Depending on their 
polarization, they display either pro-inflammatory (referred to as M1-like microglia in 
analogy with nomenclature of macrophages) or immunosuppressive phenotypes (M2-
like microglia) (Chhor et al., 2013; Hu et al., 2012; Kigerl et al., 2009). In the first week 
after injury, alternative M2-like activated microglia express immunoregulatory, anti-
inflammatory and neuroprotective factors like brain-derived growth factor (BDNF) and 
insulin-like growth factor 1 (IGF1), which support repair and regeneration after injury. 
In addition, they promote angiogenesis, matrix remodelling and suppress the release of 
pro-inflammatory cytokines, nitric oxide and other mediators of detrimental immune 
responses (Franco & Fernandez-Suarez, 2015). However, the neuroprotective M2 
response is transient and within one week after injury, the polarization pattern shifts 
towards a predominantly M1-like phenotype (Hu et al., 2012; Kigerl et al., 2009). The 
M1-like phenotype is characterized by the release of oxidative metabolites, pro-
inflammatory cytokines (IL-1, IL-6, and TNF-α) and increased phagocytic activity (Gao et 
al., 2013). This is essential for host defence but prolonged M1 activity after TBI provokes 
neuroinflammation and cell death, which in turn exacerbates progressive tissue damage 
and loss of functional brain areas (A. Kumar & Loane, 2012). 
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Table 1.1 
Class of compound Examples 
Viral, bacterial or 
fungal surface 
structures, DNA/RNA 
Agonists of members of the pattern recognition receptor families, (TLR1/2, 
TLR3, TLR4,TLR6/2 and TLR9), bacterial LPS or cell wall proteoglycans and 
lipoteichoic acid (LTA), gp41, gp120  
Abnormal endogenous 
proteins 
β-amyloid (aggregates), prion protein (PrP) 
Complement Complement factors C1q, C5a 
Antibodies Immunoglobulin (IgA, IgG, IgM), presented in immune complexes 
Cytokines 
Colony stimulating factors (M-CSF, GM-CSF), IL-1 , IL-2, IL-4, IL-6, IL-10, IL-
12, IL-15, IL-18, IFN- , TGF- , TNF-  
Chemokines 
Ligands for chemokine receptors: CCR3, CCR5, CXCR2, CXCR, CXCR4, CX3CR1, 
IL-8R 
Neurotrophic factors 
Brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor 
(GDNF), nerve growth factor (NGF), neurotrophin 3 (NT-3), NT-4 
Plasma components Albumin, fibronectin, fibrinogen, thrombin 
Other proteins and 
peptides 
Apolipoprotein E (ApoE), heat shock proteins hsp60 and hsp70, CD40L, 
melanocyte-stimulating hormone (MSH), endothelin, S100 proteins, vasoactive 
intestinal peptide (VIP) 
Neurotransmission-
related compounds 
ATP (and related purines), β-adrenergic agonists, glutamate, kainate, NMDA 
Ions K+, Mn2+ 
Other compounds 
Cannabinoids, ceramide, gangliosides, lysophosphatidic acid (LPA), melatonin, 
opioids (endomorphines), platelet-activating factor (PAF), prostaglandin E2 
(PGE2), steroid hormones, vitamin D3 
Table 1.1 Examples of signals and modulators of microglial activation. (Hanisch & 
Kettenmann, 2007) 
1.3.3 Astrocytes 
Astrocytes, the most abundant cell type in the mammalian brain, are a heterogeneous 
population of cells. For a long time, it has been assumed, that astrocytes are limited to 
their supportive function. However, studies of the last few decades have found them to 
play a much more active role. Astrocytes perform a remarkably wide range of functions. 
They control extracellular ion homeostasis, contribute to the formation of the BBB, 
regulate the local CNS blood flow and promote myelination by mature oligodendrocytes. 
They also store glycogen to break it down to lactate, which can then be transferred to 
adjacent neurons or axons during times of hypoglycaemia or intense neuronal activity 
(Brown & Ransom, 2007; Gordon, Mulligan, & MacVicar, 2007; Olsen et al., 2015; Rose & 
Verkhratsky, 2016). Furthermore, they remove surplus neurotransmitters, modulate 
formation, maturation, maintenance, and stability of synapses, and influence synaptic 
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transmission by regulated release of synaptically active molecules (Perea, Navarrete, & 
Araque, 2009).  
The reaction of astrocytes to injury and disease, referred to as reactive astrogliosis, is an 
important issue in basic and clinical neuroscience. Astrocytes are key players in the 
multicellular response to TBIs and several mechanisms are known to regulate their 
reactivation. The extent of their reaction is highly heterogeneous but correlates with the 
severity of tissue damage. Disruption of the BBB leads to an influx of cells and molecules, 
which are normally excluded from the CNS. Plasma proteins like thrombin (Nishino et 
al., 1993; Shirakawa et al., 2010) fibrinogen (Ryu, Davalos, & Akassoglou, 2009), 
endothelin (Gadea, Schinelli, & Gallo, 2008), SHH (Sirko et al., 2013) and many others 
have been shown to modulate the response of astrocytes. Mechanical stress upon tissue 
damage activates mechanosensitive ion channels, which leads to a rapid influx of Ca2+ 
and subsequently to a calcium-induced release of ATP via astrocyte connexin hemi-
channels. The resulting ATP gradient recruits microglia and other cells of the innate 
immune system to the site of injury (Burda, Bernstein, & Sofroniew, 2015). Danger-
associated molecular patterns (DAMPs) like K+, heatshock proteins, HMGB1 and 
mitochondrial DNA, which are released by injured and dying cells, initiate NFkB- 
signalling in adjacent astrocytes and induce the release of pro-inflammatory cytokines 
like tumor necrosis factor α (TNFα), α-chemokines and the inflammatory mediators 
cyclooxygenase 2 (COX2) and matrix metalloproteinase 9 (MMP-9). This, too, helps 
astrocytes to recruit microglia and other cells involved in reactive gliosis (Burda et al., 
2015; Mathew et al., 2012). HMGB1 for example stimulates endothelial cells and their 
progenitors to repair the BBB after brain injury. In an immediate response after TBI, 
astrocytes change their gene expression to increase phagocytosis of cellular debris and 
to restore the extracellular milieu. Morphological equivalents of the altered function are 
hypertrophy and the upregulation of intermediate filaments like the classical reactive 
astrocyte marker GFAP, Vimentin and Nestin (Zamanian et al., 2012).  
These changes can be observed in the course of all homeostatic disturbances in the CNS. 
In the stab wound injury model, a model for acute, penetrating CNS injuries, this early 
and ubiquitous response is followed by polarization towards the injury and the 
upregulation of proliferation genes between 3 and 5 days post injury (dpi) (Zamanian et 
al., 2012). Thus, with a peak at 5 to 7 dpi (Bardehle et al., 2013; Buffo et al., 2008; Simon 
et al., 2011; Sirko et al., 2013), proliferation of astrocytes is delayed compared to 
proliferation of NG2 glia and microglia. Notably, the behaviour of individual astrocytes 
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upon TBI is quite heterogeneous, which supports the hypothesis of various astrocytic 
subtypes with distinct functions. In vivo imaging revealed that only about one half of all 
reactive astrocytes polarise. Even less, only about 15%, reenter the cell cycle in response 
to TBI and it has also been shown, that proliferation is limited to juxtavascular 
astrocytes (Bardehle et al., 2013). Unlike microglia and NG2 glia, astrocytes do not 
migrate towards the injury site. Therefore, solely newly generated astrocytes and 
protruding processes of polarized reactive astrocytes perform the most important 
function of astrocytes in acute brain injuries: The formation of a glia limitans to protect 
vital neuronal tissue from the neurotoxic inflammatory processes in the lesion core. The 
juxtavascular position of proliferating astrocytes strongly suggests a function in 
regulating and restoring the BBB.  
Cells with an astrocytic identification also serve as neuronal stem cells during 
development and in the adult brain’s neurogenic niches, i.e., the SEZ at the lateral wall of 
the lateral ventricle, which generates olfactory blub-neurons, and the subgranular zone 
of the hippocampus, which gives rise to new neurons for the granular cell layer of the 
dentate gyrus. Reactive parenchymal astrocytes and astrocytes that function as neuronal 
stem cells in these neurogenic niches share many common features (Table 1.2).  
 
Table 1.2 
Protein Neuroepithelial 
cells 
Radial glia 
early 
Radial glia 
late 
Adult neural 
stem cell 
Mature 
astroglia 
Reactive 
astroglia 
Ependymal 
cell  
GFAP − −/+ +/++ +++ −/++ +++ + 
GLAST (Slc1a3) − ++ ++ ++ +++ +++ ++ 
GLT1 (Slc1a2) − − + ++ +++ ++ ++ 
Glutamine 
synthetase 
− − + ++ +++ +++ − 
S100-β − − + + ++ +++ +++ 
Connexin 43 (Gja1) − − ++ +++ +++ +++ ++ 
Aquaporin 4 Not defined Not defined Not defined ++ +++ +++ + 
KIR 4.1/2.1 − + ++ +++ +++ ++ ++ 
Aldlhl1 − − + + +++ +++ ++ 
Nestin (RC1/RC2) +++ +++ +++ +++ − +++ ++ 
Vimentin − + ++ +++ − +++ +++ 
BLBP ++ +++ +++ +++ − +++ − 
TN-C − +++ +++ ++ − +++ − 
Phosphacan/DSD-1 − +++ +++ +++ − ++ − 
Table 1.2 Similarities and Differences Between Glial Cell Types in Terms of Some 
Marker Gene Expressions. Adopted from Gotz, Sirko, Beckers, and Irmler (2015) 
 
But despite these similarities, reactive astrocytes do not possess the ability of long-term 
self-renewal and in-vivo neuronal generation. If astrocytes divide after injury, they do it 
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only once and always stay within their lineage. In vitro, however, the formation of 
multipotent, self-renewing neurospheres demonstrated that parenchymal astrocytes 
indeed have the intrinsic capacity to produce neurons. But only one third of all 
neurospheres derived from reactive astrocytes generate neurons, whereas all 
neurospheres derived from SEZ-neuronal stem cells do so. Hence, the different potential 
in vivo can in part, but not exclusively, be explained by cell-intrinsic differences. 
Furthermore, adult neural precursor cells transplanted to the neocortex produce only 
glial cells (Herrera, Garcia-Verdugo, & Alvarez-Buylla, 1999; Seidenfaden, Desoeuvre, 
Bosio, Virard, & Cremer, 2006), whereas in their physiological localization, they 
continuously contribute new neurons to the olfactory bulb (Lois & Alvarez-Buylla, 1994; 
Luskin, 1993) or the granule cell layer of the dentate gyrus (Seri, Garcia-Verdugo, 
McEwen, & Alvarez-Buylla, 2001). This demonstrates that brain injuries can activate 
parts of the neurogenic capacity in a subset of astrocytes. But this potential cannot be 
used to replace lost neurons. For this reason, further research has to aim to identify 
signals that retain astrocytes within their lineage in vivo, in order to pave the way for 
innovative therapeutic approaches in the treatment of traumatic brain injuries and 
other conditions correlated with a loss of neurons.  
1.4 Arylhydrocarbon receptor  
AhR was first discovered in 1976 by Poland et al. as a specific binding site for the 
environmental toxin and carcinogen 2,3,7,8-Tetrachlorodibenzo-p-dioxine (TCDD) 
(Poland, Glover, & Kende, 1976). Since then, AhR had predominantly been studied as a 
mediator of toxic TCDD-effects and became a prototype for our current understanding of 
receptor-driven toxic responses. In the last few years, however, it became evident that 
AhR is far more than a mere mediator of toxic phenomena. The AhR gene is expressed in 
many different cell types and is highly conserved throughout species, which proves its 
fundamental role in biological systems (Hahn, Karchner, Shapiro, & Perera, 1997).  
1.4.1 Protein structure  
AhR structure is determined by two functional domains: The basic helix-loop-helix 
(bHLH) and the PER-ARNT-SIM (PAS) domain. The N-terminal bHLH domain, which is 
composed of two aliphatic α-helices and an adjacent region of basic amino acids, 
mediates DNA binding and protein dimerization, whereas the PAS domain serves as 
docking site for hetero- or homodimerization with other PAS proteins or the molecular 
chaperone heat-shock protein 90 (HSP90) (Fukunaga, Probst, Reisz-Porszasz, & 
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Hankinson, 1995). A glutamine-rich transactivation domain (TAD) at the C-terminal end 
of the AhR protein allows targeted gene activation by interacting with numerous 
transcriptional co-activators (M. B. Kumar & Perdew, 1999). Nuclear transport is 
regulated via an N-terminal nuclear localization signal (NLS) and a nuclear export signal 
(NES) within the PAS domain (Ikuta, Eguchi, Tachibana, Yoneda, & Kawajiri, 1998). 
 
Figure 1.2 
 
Figure 1.2 Protein structure of mouse AhR. From Abel and Haarmann-Stemmann, 
2010 (Abel & Haarmann-Stemmann, 2010). 
 
1.4.2 AhR ligands 
AhR was initially discovered as a xenobiotic receptor and therefore, the search for 
ligands focussed mainly on polycyclic aromatic hydrocarbons (PAH) and planar 
halogenated aromatic hydrocarbons (HAH, most of all TCDD) with strong agonist 
activity. But since AhR-deficient mice showed developmental abnormalities and 
deficiencies in the immune system (Fernandez-Salguero et al., 1995; Mimura et al., 1997; 
Schmidt, Su, Reddy, Simon, & Bradfield, 1996), scientists started to look for natural AhR 
ligands. These natural ligands were found to be either exogenous ligands, introduced by 
nutrition (e.g. flavonoids and indoles), or endogenous ligands, mainly tryptophan 
metabolites (Murray, Patterson, & Perdew, 2014). These ligands show lower AhR 
affinity and elicit less toxic responses from the AhR pathway.  
Lipids, cAMP or bilirubin can also activate AhR (Denison, Soshilov, He, DeGroot, & Zhao, 
2011). Since structures of these natural agonists differ extremely from the classical HAH 
and PAH structures, the ligand-binding site of AhR must be highly promiscuous and 
might bind far more exogenous and endogenous molecules than we currently know. 
Different ligands have different binding affinities and metabolic degradation. PAHs and 
most natural ligands cause only a temporally limited AhR activation, whereas HAHs like 
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TCDD induce permanent AhR-dependent gene expression, which is responsible for AhR-
dependent toxicity (Denison et al., 2011). 
1.4.3 Regulation of AhR 
1.4.3.1 Canonical pathway 
AhR is a ligand-dependent transcription factor. In absence of a ligand, AhR is restrained 
in the cytoplasm by a chaperone complex, consisting of an Hsp90 dimer and the co-
chaperones p23 and AIP (AhR-interacting protein) (Petrulis & Perdew, 2002). The binding 
of a ligand induces phosphorylation of two protein kinase C sites adjacent to the nuclear 
localization sequences (NLS), which enables importin β to recognize the NLS and to 
shuttle the AhR–Hsp90–AIP complex into the nucleus. Here, AhR has to dissociate from 
Hsp90 in order to heterodimerize with ARNT (AhR nuclear translocator), another 
member of the basic helix–loop–helix Per-ARNT-Sim (bHLH/PAS) protein superfamily 
(Heid, Pollenz, & Swanson, 2000). This AhR–ARNT heterodimer then binds to regulatory 
regions of its target genes, the so called xenobiotic responsive elements (XRE), and when 
bound to DNA, it recruits components of the general transcription machinery to loosen 
the chromatin structure and to initiate transcription by RNA polymerase II (Hankinson, 
2005; Hestermann & Brown, 2003). AhR target genes mainly encode for enzymes 
involved in phase I and II drug metabolisation and for proteins that regulate cell growth 
and differentiation (Bock & Kohle, 2006). 
 
Figure 1.3 
  
Figure 1.3 Canonical AhR pathway. From Abel and Haarmann-Stemmann, 2010 (Abel 
& Haarmann-Stemmann, 2010) 
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1.4.3.2 AhR crosstalks 
Apart from the canonical pathway described above, several alternative effect 
mechanisms are described in literature. Ligand binding of AhR releases c-src, a tyrosine 
kinase and part of the cytosolic AhR complex. The active c-src subsequently translocates 
to the cell membrane, phosphorylates EGFR, and thereby initiates EGFR signalling via 
the MAPK pathway (Haarmann-Stemmann, Bothe, & Abel, 2009; Xie, Peng, & Raufman, 
2012). Notably, the activation of EGFR in response to ligand binding works also in cell- 
and nucleousfree conditions (Enan & Matsumura, 1995). Thus, the crosstalk with the 
EGFR must be completely independent from the canonical nuclear pathway and from 
associated changes in gene transcription.  
 
Figure 1.4 
  
Figure 1.4 Cross-talk of AhR and EGFR signal transduction. From Haarmann-
Stemmann et al. 2009 (Haarmann-Stemmann et al., 2009) 
 
Furthermore, interactions with retinoblastoma protein (RB), Nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB), estrogen or androgen receptors, tumor 
necrosis factor-α (TNF-α), and transforming growth factor-β (TGF-β) have been 
described (Haarmann-Stemmann et al., 2009; Ohtake, Fujii-Kuriyama, & Kato, 2009; 
Puga, Ma, & Marlowe, 2009; Tian, 2009). 
1.4.4 Physiological functions of AhR 
AhR in the immune system helps to control the extent of inflammatory reactions in 
barrier organs like skin, gut and lung. (Reviewed in: (Stockinger, Di Meglio, Gialitakis, & 
Duarte, 2014)). It is highly expressed in Th17 cells and to lower extents also in 
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regulatory T-cells (Treg), but not in type 1 and type 2 T-helper cells (Veldhoen et al., 
2008). The effects of AhR activation on Treg and Th17 differ greatly among different 
experimental settings and seem to be ligand dependent (Quintana et al., 2008). B-cells 
also upregulate the expression of AhR upon activation, and AhR activation by TCDD 
inhibits B-cell differentiation into plasma cells (Sulentic & Kaminski, 2011). In 
macrophages, AhR activation supports M2 differentiation. M2 macrophages produce 
high levels of IL-10 and thereby restrict inflammatory responses and protect against 
persistent inflammation. Correspondingly, activation of macrophages in AhR deficient 
mice increases production of pro-inflammatory cytokines such as IL-6 (interleukin-6), 
IL-12 and TNF-α, which are typically secreted by M1 polarized macrophages (Biswas & 
Mantovani, 2010; Kimura et al., 2009). 
During development, AhR is involved in the differentiation of many organ systems by 
regulating the expansion and differentiation of progenitor cells. At least in liver 
progenitors, altered differentiation and proliferation could be traced back to a 
downregulation of Wnt/β-catenin pathway target genes (Prochazkova et al., 2011). 
Induction of AhR signalling arrests proliferation of intrathymic lymphocyte progenitor 
cells (Laiosa et al., 2003), whereas attenuating AhR signalling promotes the expansion of 
human hematopoietic stem cells (Boitano et al., 2010; Rentas et al., 2016). 
Since loss of AhR in stem cells regularly results in a loss of quiescence and since 
prolonged or inappropriate stimulation of AhR attenuates stem cells proliferation, 
balancing stem cell quiescence, proliferation, migration, and differentiation is assumed 
to be the principal physiological task of AhR (Gasiewicz, Singh, & Bennett, 2014). 
1.4.5 AhR in the CNS 
The physiological function of AhR in the CNS is not very well understood. Similar to its 
effects in macrophages, ligand-dependent AhR activation restricts microglial activation 
(Lee et al., 2015; Rothhammer et al., 2018), and in a model of experimental autoimmune 
encephalomyelitis (EAE), interferon (IFN)-β-induced AhR signalling in astrocytes 
reduced CNS inflammation (Rothhammer et al., 2016). Thus, AhR activity seems to 
attenuate inflammatory processes in the CNS. Following cerebral ischemia however, 
AhR activation worsened the outcome, whereas treatment with AhR antagonists had 
neuroprotective effects (Cuartero et al., 2014). Taken together, the impact of AhR 
signalling in the injured or diseased CNS still remains uncertain and depends inter alia 
on the way of AhR activation or inactivation and the disease model used. 
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During embryonic development, neuronal precursor cells express high levels of AhR, 
and TCDD-induced AhR activation impairs their proliferation in a concentration 
dependent manner (Latchney et al., 2011). In the adult mouse brain, AhR activation 
impairs proliferation of neural progenitor cells in the dentate gyrus (Latchney et al., 2011) 
and deletion of AhR in cerebellar granule neuron precursors compromises neurogenesis 
(Dever et al., 2016).  
In the injured adult zebrafish telencephalon, AhR pathway is specifically regulated in a 
subpopulation of ependymogia in the dorsal subventricular zone. Under physiological 
conditions, AhR signalling is downregulated within 2 dpi and returns to normal levels 
within 7 dpi. Maintaining AhR signalling at high levels by vetricular injections of an AhR 
agonist changes the fate of ependymoglia towards the production of new neurons at the 
expense of ependymocyte proliferation. Persisting inhibition of the AhR pathway 
accordingly increased ependymocyte proliferation. This demonstrates the critical role of 
the AhR pathway in maintaining the balance between neuronal differentiation and 
maintenance of the stem cell pool in the adult zebrafish brain.  
1.5. Aims of the thesis 
Given the important role of AhR signalling in differentiation of neuronal progenitors in 
the zebrafish telencephalon in response to traumatic brain injuries, the main purpose of 
my thesis was to elucidate, weather AhR signalling also plays a role in neurogenesis and 
reactive gliosis of the adult mouse brain. Therefore I addressed following questions: 
1. Where is AhR expressed in the intact mouse brain? 
2. Which cells express AhR in the injured mouse brain? 
3. How does AhR activation affect reactive gliosis? 
Thus, I first determined the expression pattern of AhR in the intact and injured mouse 
brain. Afterwards the effects of AhR activation on reactive gliosis were investigated in 
vivo. Since specifically reactive astrocytes were found to express AhR in the lesioned 
cerebral cortex, I also analysed the impact of AhR activation on reactive astrocytes´ stem 
cell properties in vitro. Finally, we performed a proteome analysis to get an idea by 
which mechanisms AhR signalling affects reactive gliosis and stem cell properties of 
reactive astrocytes. 
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2 Materials 
2.1 Immunocytochemistry and Immunohistochemistry 
2.1.1 Primary Antibodies 
Table 2.1  
Antigen 
 
labelled cell type 
/ structure 
Host-
anima
l 
Working dilution  
IC= Immunocytochemistry  
IH =immunohistochemistry  
Pretreatme
nt 
 
Supplier 
AhR cells expressing 
AhR 
rabbit 1:5000 (tyramide kit) 
(0,5% Tx, 10% NGS) 
 Biomol, 
031714-
FITCH 
BrdU cells undergoing 
S-phase during 
BrdU 
administration 
rat 
IgG2a 
1:200 
(0,5% Tx, 10% NGS) 
1h 2N HCl, 
2x15 min 
borate 
buffer 
(pH8.0) 
Abcam,  
Ab-6326-
250 
DCX immature 
neurons 
guinea 
pig  
1:1000 (IH) 
1:2500 (IC) 
(0,5% Tx, 10% NGS) 
 Millipore,  
AB5320 
GFAP adult NSC, 
(reactive) 
astrocytes 
mouse 
IgG1 
1:500 (IC) 
1:200 (IH) 
(0,5% Tx, 10% NGS) 
 Sigma,  
G3893 
Iba1 microglia rabbit 1:500 
(0,5% Tx, 10% NGS) 
 WAKO 
019-
19741 
Ki67 cells in the active 
phases of the cell 
cycle (G1, s, G2, M-
phase) 
rabbit 1:500 
(0,5% Tx, 10% NGS) 
30 min 
Antigen 
retriever 
Novocastr
a 
NCL-
Ki67p 
Ki67 rat 1:300 
(0,5% Tx, 10% NGS) 
30 min 
Antigen 
retriever 
DAKO 
M7249  
Nestin  mouse 
IgG1 
1:200 
(0,5% Tx, 10% NGS) 
 Millipore 
MAB 5326 
NeuN mature neurons mouse 
IgG1 
1:80 
(0,5% Tx, 10% NGS) 
30 min 
Antigen 
retriever 
Millipore 
MAB 377 
NG2 oligodendrocyte 
precursor cells 
rabbit 1:250 
(0,5% Tx, 10% NGS) 
 Millipore 
AB 5320 
O4 late 
oligodendrocyte 
progenitors 
mouse 
IgM 
1:200 
(10% NGS) 
 Millipore 
MAB 345 
Olig2 initially 
proliferating 
NG2+ progenitors 
rabbit 1:200 
(0,5% Tx, 10% NGS) 
 Millipore 
AB 9610 
Table 2.1 Primary antibodies 
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2.1.2 Secondary antibodies 
Immunocytochemistry and Immunohistochemistry were performed with the 
appropriate species- or subclass-specific secondary antibodies conjugated to either 
AlexaFluor 488, AlexaFluor 543 or AlexaFluor 633 (1:1000, Life technologies). For signal 
amplification with the tyramide kit, biotinylated secondary antibodies (goat anti-rabbit 
biotin; 1:1000; Vector: BA-1000) were used. 
2.2 Buffers and solutions 
Phosphate-buffered saline (PBS):  
NaCl    137 mM 
KCl    2.7 mM 
Na2HPO4·7H2O 8.3 mM 
KH2PO4   1.4 mM 
 
Storing solution 
 Glycerol   30 ml 
 Ethyleneglycol 30 ml 
 H2O   30 ml 
 PO4-buffer 10x 10 ml 
 (13.8 g Na2HPO4·7H2O; 3 g NaOH, 40 ml H2O) 
 
Borate buffer 0.1 M pH 8.5 
 Na2B4O7 20.1 g 
 H2O  1,0 l 
 HCl  adjust pH to 8.5 
 
PFA 4%  pH 7.3 
 PFA  40 g 
 NaOH   3 pellets 
 PBS   900 ml 
 HCl  adjust pH to 7.3 
 
NP40 buffer  pH 7.4  
Tris-HCl, 50 mM 
NaCl  150 mM 
NP40  1% 
 
UA buffer: Urea (Sigma U5378) buffer,  
Urea   8 M in  
Tris/HCl; 0.1 M; pH 8.5 
 
Solution 1:   pH adjusted to 7.5 
D/Glucose stock: 300 mg/ml; 9 ml 
HEPES  1 M; 7.5 ml 
HBSS 1X fill up to 500 ml 
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Solution 2:   pH adjusted to 7.5 
Sucrose  154 g 
HBSS   fill up to 500 ml 
 
Solution 3:   pH adjusted to 7.5 
HEPES  10 ml 
BSA   20 g 
EBSS   fill up to 500 ml 
 
Neurosphere Medium:  
DMEM/ F12 + Glutamax 48 ml 
B27 supplement   1 ml 
Pen/Strep    0.5 ml 
Hepes buffer, 1 M   0.5 ml 
 
Anesthesia solution 
NaCl (0.9 mg/ml)  2.5 ml 
Ketamin  1 ml 
Rivapoun  0.25 ml 
 
MMF (Sleep) mix 
Fentanylcitrat 0.25 ml 
Midazolam   0.5 ml 
Medetomidin  0.25 ml 
NaCl (0.9%)  4 ml 
 
Awake mix 
Naloxon  1.5 ml 
Flumazenil   2.5 ml 
Atipamezol   0.25 ml 
NaCl (0.9%)  0.75 ml 
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2.3 Tissue culture reagents 
Reagents used for tissue culture experiments. 
Reagent Company Ordering 
Number 
B-27 Serum-Free Supplement Gibco (Life technologies) 17504044 
Bovine serum albumin (BSA) Sigma A9418 
D-Glucose (Stock 45%) Sigma G8769 
DMEM:F12 (Dulbecco's Modified 
Eagel Medium:Nutrient Mixture 
F12) + GlutaMAX 
Gibco (Life technologies) 31331 
DMSO Sigma D2438 
DNAse I Roche 1284932 
EBSS (Earle’s Balanced Salt 
Solution)  
Gibco (Life technologies) 14155063 
EGF (Epidermal Growth Factor)  Roche 855573 
FCS (Fetal Calf Serum) Pan 2602-P290705 
FGF2 (Fibroblast Growth Factor-
2) 
Roche 10555400 
HBSS (Hank's balanced salt 
solution) 
Gibco (Life technologies) 24020 
HEPES (1M) Gibco (Life technologies) 15630 
Hyaluronidase Sigma H3884 
Penicillin/Streptomycin 
(Pen/Strep) 
Gibco (Life technologies) 15140 
Poly-D-Lysine (PDL) Sigma P0899 
Sucrose Sigma S0389 
TCDD Sigma 48599 
Trypsin Sigma T4665 
Trypsin (EDTA), 0.05% Gibco (Life technologies) 25300 
2.4 Reagents for proteomic 
Reagents used for FASP 
Product Company Ordering 
Number 
2-Iodacetamid Merck 8047440025 
Acetonitrile Merck 1000301000 
Ammoniumbicarbonat Sigma A6141 
Dithiothreitol Sigma D7701 
Lys-C  Wako 125-05061 
Trifluoroacetic acid Sigma T6508 
Trypsin  Promega V511A 
Urea  Sigma  U5378 
2.5 Animal treatment 
Product Company Ordering 
Number 
20G x 1,5” feeding needle 1,9mm 
Tip 
Cadence science 9921 
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Corn oil Sigma C8267 
V-Lance knife, 19g  Alcon 8065911901 
 
Chemical  Company  Ordering Number 
4,6-dasmindino-2-phenylindol 
(DAPI) 
AppliChem  A1001 
5’-bromo-2’-deoxyuridine (BrdU)  Sigma  16880 
Agarose  Biozym 870055 
Bovine serum albumin (BSA)  Sigma  A9418 
EDTA  Merck  1084180250 
Ethanol  Merck  107017 
Glycerol  Sigma  3783 
Glycerol Sigma 3783 
Glycine  AppliChem  A4554 
HEPES  Roth  9105 
Hydrochloric acid (32%) Merck  109057 
Hydrogen peroxide  Roth  8070 
Isopropanol  Merck  1096342500 
Normal goat serum (NGS)  Vector Laboratories  S-1000 
Paraformaldehyde (PFA)  Roth 0335 
Potassium chloride Merck  104936 
Potassium dihydrogen phosphate 
(KH2PO4) 
Merck 104873 
Sodium hydroxide  Roth 6771 
Sodium phosphate (Na2HPO4•7H2O) Merck T876 
Triton-X100  Roth  3051 
Tris-HCl (1M) Rockland MB004 
H2O2 (30%) Sigma 31642 
 
2.6 Kits 
Kit Company Ordering number 
Tyramide Signal Amplification kit 
Plus Fluorescein System 
Perkin Elmer NEL741 
TSA™, Plus Tetramethylrhodamine 
(TMR) System  
Perkin Elmer NEL742 
streptavidin-HRP conjugate Perkin Elmer NEL750 
RNeasy Mini Kit Qiagen 74106 
Maxima First Strand cDNA Synthesis 
Kit for RT-qPCR 
Invitrogen K1642 
 
2.7 PCR Primers 
Kit Sequence 
mouseCyp1a1for  AGAGGTTGGCGACTTTGACCCTTA 
mouseCyp1a1rev ACCTCCCGAAACTGATTGCTGAGA 
mouseRpl13for TTCGGCTGAAGCCTACCAGAAAGT 
mouseRpl13rev GCATCTTGGCCTTTTCCTTCCGTT 
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3 Methods 
3.1 Animals  
3.1.1 Mouse strains 
C57BL/6J mice at the age of 8 to 10 weeks were used for all experiments. 
3.1.2 Stab wound injury 
Animals anaesthetized by i.p. injection of 400 µl “Sleep” (20 ml/kg bodyweight), 
sustained a 0.6 mm deep and 1.0 mm long stab wound in the somatosensory cortex of 
the right hemisphere. Using the V-Lance knife under the control of a stereotactic device 
guaranteed a reproducible injury size and location (0.6 mm in depth, 1.5 mm lateral and 
from 1.0 mm to 2.0 mm caudally from the bregma) (Figure 3.1). I.p. injection of 400 µl 
“Awake” reversed anaesthesia after the intervention.  
 
Figure 3.1  
 
Figure 3.1 Localisation of the stab wound. Stab wound was located 1.5 mm lateral 
and from 1.0 mm to 2.0 mm caudally from the bregma and reached to 0.6 mm in depth. 
Scale units: mm  
 
3.1.3 Oral TCDD administration 
Every second day mice of the experimental group obtained TCDD, diluted in 150 µl corn 
oil to a final concentration of 0.346 µM by oral application. The first TCDD-
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administration was 5 h prior to the performance of the stab wound. The second and the 
third gavage took place at 2 and 4 dpi. At the end of one experiment each animal was 
exposed to 0,156 nmol TCDD dissolved is 450 µl of corn oil (Figure 3.2). Animals that 
were not exposed to TCDD underwent the same treatment but were gavaged with corn 
oil only.  
 
Figure 3.2 
 
Figure 3.2 Schedule of systemic TCDD treatment. For systemic treatment, mice were 
gavaged 3 times (0 dpi, 2 dpi and 4 dpi) with TCDD diluted in corn oil or with the vehicle 
only.  
 
3.1.4 Local TCDD administration 
For local TCDD treatment, animals underwent a second surgery at day 3 post injury. 
(Anaesthesia: see stab wound injury). 0.2 pmol TCDD dissolved in 1 µl artificial CSF and 
1.28 nl DMSO or respectively the same amount of DMSO and aCSF only were injected in 
the centre of the stab wound (coordinates from bregma: x= -1.0 mm; y= -1.5 mm; z= -0.6 
- -0.2 mm) with an extended capillary and an infusion speed of 2 µl/sec (Figure 3.3). 
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Figure 3.3
 
Figure 3.3 Schedule of local TCDD treatment. For local treatment, TCDD was injected 
directly into the stab wound at 3 dpi.  
 
3.2 Histology 
3.2.1 BrdU labelling 
BrdU, a thymidine analogue incorporates into newly synthesized DNA and can be 
detected by specific antibodies. Therefore, a continuous administration of BrdU in the 
drinking water (1 g BrdU per 1 l water) from 1 dpi (for systemic TCDD treatment) or 
immediately after the second surgery (for local TCDD administration) until sacrifice at 5 
dpi, allows visualization of all cells undergoing S-phase in this period.  
3.2.2 Perfusion and preparation of free floating vibratome sections 
Transcardial perfusion 5 days after injury fixed the brain tissue. Animals anesthetised by 
i.p. injection of Ketamin (Ketaminhydrochlorid; 100 mg per 1 kg of body weight) and 
Rompun (Xylazinhydrochlorid; 20 mg per kg body weight) were first perfused with PBS 
to wash blood out, followed by approximately 50 ml of PFA 4% in PBS.  
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Brains were removed, post fixed in 15 ml PFA 4% for 2 h at 4 °C, washed with PBS and 
embedded in 3% agarose in PBS to be finally cut with the vibratome into 60 µm thick 
slices.  
Sections collected in PBS were kept at 4 °C for immediate use or transferred to storage 
solution for long time storage at -20 °C.  
3.2.3 Immunohistochemistry 
3.2.3.1 Standard protocol 
Indirect antigen labelling requires two steps. First sections were incubated over night at 
4 °C with primary antibodies, recognizing the antigens of interest, followed by 2 hours of 
incubation at room temperature with subclass specific secondary antibodies which are 
conjugated to fluorescent dyes (Alexa 488, Alexa 543, Alexa 647) or tagged with biotin 
to visualize the antigen bound primary antibody.  
All antibodies were diluted in 0.1 M PBS containing 0.5% Triton-X-100 to permeabilize 
cell membranes and non-specific binding was reduced by addition of 10% NGS as well as 
three washing steps with PBS following each antibody incubation. 
Finally sections were put on a microscope slide, topped with a drop of mounting 
medium and covered with a cover slide. 
3.2.3.2 Antigen retrieval 
Some antigens are inaccessible for antibodies (BrdU) or get masked during tissue 
fixation. Therefore, some epitopes demand special pretreatments (see Table 2.1) 
3.2.3.3 DNA denaturation with HCl 
BrdU can only be detected in single stranded DNA. Consequently it was necessary to 
denature DNA with 2 M HCl for 30 minutes at room temperature and neutralize the acid 
with 0.1 M sodium tetraborate buffer (pH 8.5) for 30 minutes afterwards. 
3.2.3.4 Target retrieval solution  
Target retrieval solution, diluted 1:10 in water, was heated to 100°C and put on sampels 
for 30 minutes to loose fixation induced, epitope masking protein crosslinks. After 
incubation, sections were washed three times with PBS and stained as described above. 
3.2.3.5 Signal amplification 
Tyramide Signal Amplification (TSA™) technology enabled the detection of AhR, what 
was impossible with the standard protocol. After incubation with the primary antibody, 
(see “Immunohistochemistry - general treatment) pre-treatment with saturating 
amounts of hydrogen peroxide (0.3% in PBS) for 30 minutes was necessary to inactivate 
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endogenous peroxidase activity and avoid unspecific deposition of fluorophore 
tyramides later on. 
Incubation with a biotinylated secondary antibody (1h room temperature; dilution: 
1:1000 in blocking solution) provides binding sides for streptavidin. During the 
incubation time of 1 hour horseradish-peroxidase coupled streptavidin (diluted 1:100 in 
PBS) binds to biotin and therefor immobilizes horseradish-peroxidase at that position 
where the antigen of interest was initially bound by the primary antibody.  
The enzymatic activity of horderadish-peroxidase converts the fluorophore tyramides 
(Fluorescein or Tetramethylrhodamine diluted 1:100 in amplification diluent) into an 
extremely reactive intermediate that binds within 5 minutes to adjacent proteins.  
Three washing steps with PBS followed every individual step of the protocol. 
 
Figure 3.4 
 
Figure 3.4 Schematic representation of TSATM detection applied to 
immunolabeling of an antigen. Adopted from Thermo Fisher Scientific´s Manual for 
Tyramide Signal Amplification Kits1 
 
3.3 Neurosphere assay 
3.3.1 Dissection and dissociation of adult mouse SEZ and cortex for culture of primary 
neurospheres 
After cervical dislocation and decapitation, brains were removed and stored in ice-cold 
HBSS containing 10 mM Hepes until their immediate dissection in the same medium.  
Cortical grey matter was taken with a punch of 3.5 mm in diameter and to isolate the 
SEZ, brains were cut coronally at the level of the optic chiasm and separated into the two 
hemispheres. After removal of the hippocampus to expose the SEZ, it was then 
                                                        
1 https://tools.thermofisher.com/content/sfs/manuals/mp20911.pdf; last visited: 
01/09/2018 
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separated from underlying striatum by cutting out a thin layer of tissue. (Fischer et al., 
2011) 
Samples collected on ice in 2 ml dissociation medium were then split into single cells by 
a combination of mechanical and enzymatic dissociation. Two steps of incubation at 37 
°C for 15 minutes digested the extracellular matrix and pipetting tissue pieces up and 
down with a 1 ml pipette tip before and following each incubation step supported the 
production of a single cell suspension.  
Subsequent addition of 3 ml solution III stopped the activity of trypsin.  
The cell suspension was then transferred though a 70 µm strainer into a new falcon tube 
and centrifuged for 5 min at 1200 rpm (200 g).  
Next, the supernatant was removed, cells were resuspended in 10 ml solution II 
containing 30% of sucrose, and centrifuged for 10 min at 2000 rpm. Dead cells fail to 
precipitate under these conditions and can be removed with the supernatant.  
Pelleted cells were resuspended in 2 ml ice cold solution III and added to another 10 ml 
solution III in a new 15 ml Falcon tube, centrifuged again for 7 min at 1500 rpm and 
seeded at a cell density of 15.000 to 25.000 cells/5 ml neurosphere medium in a cell 
culture flask (for SEZ neurospheres) or 6-well plates (for ipsi- and contralateral cortical 
spheres).  
All centrifugation steps were performed in a Hettich Rotana 460R Centrifuge at 4 °C. 
Incubation lasted 1 (SEZ) or 2 weeks (cortex ipsi- and contralateral) at 37 °C with 95% 
air and 5% CO2. Every third day, fresh EGF and FGF2 were added at a final concentration 
of 10 ng/ml (SEZ) or 20 ng/ml (cortex ipsi- and contralateral). 
3.3.2 Passage of neurospheres 
To reveal the neurospheres self-renewing capacity, spheres were split by enzymatic 
dissociation with 0.05% trypsin-EDTA and re-plated as single cells at a density of 5.000 
cells per millilitre.  
Cortical spheres were split separately. Therefor single spheres were picked with a 200 
µl pipette tip, transferred into 1.5 ml tubes filled with 0.2 ml 0.05% trypsin-EDTA and 
incubated for 5 minutes at 37 °C. After addition of 0.3 ml solution III to stop trypsin 
activity, a single cell suspension was generated by pipetting neurospheres up and down 
with a 200 µl pipette tip.  
Centrifugation at 200 g for 5 min (Eppendorf Centrifuge 5415D) pelleted the cells, which 
were then resuspended in 0.5 ml neurosphere medium containing 10 to 20 ng EGF and 
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FGF and plated in 48 well plates. At the end each well contained 0.5 ml medium together 
with all cells derived from one single sphere  
SEZ spheres were split as a bulk. For this purpose all spheres were collected in a 15 ml 
falcon tube and centrifuged down for 5 min at 200 g. The supernatant, passed through a 
20 µm filter, served as conditioned medium.  
A single cell suspension was also generated by incubation for 5 minutes at 37 °C in 0.75 
ml 0.05% trypsin-EDTA, whose activity was stopped afterwards with an equal amount 
of solution III, and mechanical dissociation with a 200 µl pipette tip. Centrifugation for 5 
min at 1000 rpm at 4 °C in a Hettich Rotana 460R Centrifuge separated supernatant and 
cells which were subsequently resuspended in a mixture of fresh and conditioned 
neurosphere medium and plated at a density of 5 cell/µl in a cell culture flasks. 
3.3.3 Differentiation of neurospheres and immunocytochemistry 
This part of the neurosphere assay provides evidence of the spheres´ mulitpotency. SEZ 
neurospheres within neurosphere medium were directly transferred into 24-well plates 
containing PDL coated glass cover slips and the next day, neurosphere medium was 
replaced by differentiation medium.  
Cortical spheres were picked separately with a 200 µl pipette, placed on a poly-ornithine 
(PORN) and laminin coated glass coverslip which was covered with 100 µl 
differentiation medium and after 2 h, when spheres attached to the substrate, wells 
were filled completely with differentiation medium. 
After 7 days neurospheres were fixed for 15 minutes with 4 % PFA and stained as 
described in Histology -> Immunohistochemistry -> standard protocol. 
3.4 Data analysis 
3.4.1 Quantification of marker positive cells in brain sections 
The number of marker positive cells was assessed at an Olympus FV1000 laser-scanning 
confocal microscope with optical sections of 1 μm in at least 3 vibratome sections per 
brain. Immunohistochemically labelled cells around the stab wound were quantified per 
volume in the region of 300 µm lateral and medial to the lesion core and up to a depth of 
600 µm from the cortical surface. Proliferating cells in the SEZ were counted in coronal 
sections along the whole lateral length of the ventricle and normalized to the 
corresponding area. 
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3.4.2 Neurospheres 
Differentiated and stained neurospheres were analysed with a Zeiss Axioplan2 light 
microscope and to measure the size of SEZ neurospheres, Zeiss AxioVision 4.8 
microscope software was used.  
3.4.3 Statistics 
Shapiro–Wilk test designated whether data sets are in conformity with normal 
distribution and, accordingly, Mann-Whitney-U-test or two-sample t-test were used to 
test for statistical significance. Since it is impossible to test for normal distribution in 
samples smaller than five, t-test was performed in all these cases. T-test is relatively 
robust against violation of the assumption for standard distribution and in simulations 
with very small sample sizes, the type I error rate normally does not exceed the nominal 
value of 5%. Compared to alternative tests, t-test provides high power, an important 
feature in hypothesis generating testing (De Winter, 2013).  
Data were considered significant with p<0.05 (*), very significant with p<0.01 (**) and 
highly significant with p<0.001 (***). All error bars present standard errors of the mean 
(± S.E.M). 
3.5 Proteomic 
3.5.1 Filter aided sample preparation (FASP) 
LC-MSMS-based comparative Proteomics detected quantitative changes in protein 
expression. Therefore the cortical gray matter round the stab wound or an identical area 
of unlesioned cortex was isolated at 5 dpi with a punch of 2.5 mm in diameter, collected 
in 125 µl NP40-buffer and stored at -80 °C. 
To set up samples for filter-aided sample preparation, they were defrosted and lysed in 
NP40-buffer by repetitive cycles of sonification for 10 sec, vortexing and cooling down 
on ice.  
Following a Bradford protein assay to determine the lysates protein concentrations, 20 
µg proteins of each sample in 400 µl UA buffer were denatured by adding 4 µl 1M DTT 
for 30 minutes at 60 °C and alkylated with 40 µl 300 mM IAA in another 400 µl of UA 
buffer for 30 min at room temperature in the dark.  
The obtained protein solutions were transferred to a filter unit (Microcon YM-30) and 
centrifuged for 15 min at 14,000 g before washing the filter membrane three times with 
200 µl UA buffer and twice with 100 µl 50 mM ABC buffer.  
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Afterwards exposure to 1 µg Lys-C in 40 µl 50 mM ABC buffer for 2 h at RT started 
protein digestion on the membrane and resulting peptides could be centrifuged (14.000 
g; 15 min) through the filter and collected in a new LoBind Eppendorf cup (2 ml).  
The remaining material on the filter underwent an additional digestion step at 37 °C 
over night with 2 µg Trypsin in 10 µl ABC buffer. Peptides were also centrifuged through 
the filter and collected in another LoBind Eppendorf cup (2 ml). 
Both eluates were acidified with Trifluoroacetic acid (TFA) to a pH of 2 and finally 
subjected to LC-MS/MS. (Hauck et al., 2010) 
3.5.2 Validation of AhR activation 
RNA was isolated from liver tissue of animals used for proteome analysis using the 
Rneasy Mini kit (Qiagen) according to the manufacturer’s recommendation including the 
digestion of remaining genomic DNA. Upregulation of CYP1A1, a biomarker for AhR 
activation, upon systemic TCDD treatment has been confirmed by qPCR.  
3.5.2.1 cDNA Synthesis 
2.5 µg RNA of each liver sample served as a template for cDNA synthesis using the 
Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Invitrogen) according to 
manufacturer’s protocol. 
Raction temperature:  15 min  25 °C 
    30 min 50 °C 
    5 min  85 °C 
3.5.2.2. Real Time PCR (RT-PCR) 
Expression levels of Cyp1A1 were determined by quantitative Real Time PCR on a DNA 
Engine OpticonTM machine (Biorad) using SYBR Green mastermix (Biorad) to stain and 
quantify double-stranded DNA.  
Cyp1A1 levels were expressed relative to the concentration of the housekeeping gene 
RLP13 as 2-(ΔCt), while ΔCt is the difference in the number of cycles that is necessary to 
achieve a certain amount of DNA represented by threshold levels of fluorescence.  
Conditions for the RT-PCR:  
Initialising  95 °C 5 min 
Denaturation  95 °C 30 sec 
Annealing   60 °C 30 sec  40 cycles 
Elongation  72 °C 30 sec 
Final elongation 72 °C 10 min 
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4 Results 
4.1 AhR expression in the adult mouse brain 
Until few years ago, our knowledge about AhR signalling had been limited to the 
induction of xenobiotic metabolizing enzymes in response to environmental pollutants 
and, even though, more and more studies focus on the physiological roles of AhR, only 
very little is known about its expression and function in the central nervous system 
(Cuartero et al., 2014; Latchney, Hein, O'Banion, DiCicco-Bloom, & Opanashuk, 2013; 
Latchney et al., 2011; Petersen et al., 2000). Hence, my first aim was to evaluate the 
existence of AhR in the adult mouse brain using immunohistochemistry. This technique 
makes it possible to visualize the exact anatomical distribution of AhR as well as its 
localization within single cells. Thus, immunohistochemical stainings reflect the 
situation in vivo, when they are performed in tissue sections.  
 
Figure 4.1 
 
Figure 4.1 AhR expression pattern in the intact adult mouse brain. Coronal brain 
sections stained against AhR and GFAP. In the intact brain AhR is only detectable in the 
dentate gyrus of the hippocampus (a). AhR was not detectable in the SEZ (b), the intact 
cortex (c), the cerebellum or the mid brain (not shown). 
Scale bars: 100 µm; RMS = rostral migratory stream; SEZ = subependymal zone 
 
The expression of AhR-mRNA in neural progenitor cells of the dentate gyrus  the part 
of the hippocampus, where adult neurogenesis occurs  has previously been reported 
(Latchney et al., 2013) and immunohistochemical stainings accordingly confirmed these 
results (Figure 4.1 a). Strikingly, the second main neurogenic niche in the adult 
mammal brain, the subependymal zone, did not exhibit detectable levels of AhR (Figure 
4.1 b) and AhR was also abscent in the cerebellum and the mid brain.  
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AhR expression in the intact cerebral cortex was below the detection range, too (Figure 
4.1 c). But this changed after brain injuries. AhR levels were not detectable until 24 
hours post injury (Figure 4.2 a), peaked at 3 dpi (Figure 4.2 b) and persisted at least 
until 5 dpi (Figure 4.2 c). Here it is remarkable that AhR appeared simultaneously with 
the upregulation of GFAP in astrocytes, the classical indicator for reactive gliosis in the 
central nervous system. Immunoreactivity for AhR was highest right beside the site of 
injury and regressed gradually over 300 to 400 µm. In the intact contralateral cortex, 
AhR had at no time been detectable.  
 
Figure 4.2 
 
Figure 4.2 AhR immunostaining in response to stab wound injury. Coronal brain 
sections stained against AhR and GFAP. Stab wound injury of the cortex induced distinct 
expression of AhR simultaneously with the upregulation of GFAP in reactive astrocytes. 
Confocal images show AhR expression in the lesioned cortex at different time points 
after stab wound injury: 1 dpi (a), 3 dpi (b) and 5 dpi (c). Dashed lines indicate the site 
of injury. Scale bars: 100 µm 
 
Reactive gliosis, the universal response to brain injuries, involves the reaction of various 
cells from different lineages, whereby astrocytes, oligodendrocytes and microglia play a 
key role. Since different cell types have diverse functions in that process of wound 
closure and tissue repair, it is essential to know which cell types express AhR in order to 
investigate its potential role in reactive gliosis. For this reason I stained tissue sections 
from the injured brain for specific glial cell markers (astrocytic GFAP, microglial Iba1 or 
Olig2 plus NG2 for cells of the oligodrendrocytic lineage) and examined them for 
colocalization with AhR.  
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Figure 4.3 
 
 
Figure 4.3 AhR immunostaining of different glial cell types. Immunostaining against 
AhR and markers for different glial cells in sections of the injured cortex at 5 dpi. There 
was no colocalization of NG2 (oligodendrocyte progenitor cells) (a-a´´) or Iba1 
(microglia) (b-b´´) while all AhR+ cells proved to be GFAP+ reactive astrocytes (c-c´´). 
Scale bars: 25 μm 
 
Microglia, the immune cells in the central nervous system, are the first cells that get 
activated after brain injury. They proliferate, migrate towards the site of lesion, 
phagocytose debris and activate the other glial cells, including NG2+ oligodendrocyte 
progenitor cells and astrocytes. Several studies imply that AhR plays a role in the 
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activation of microglia at least in vitro (Lee et al., 2015; Xu et al., 2014). However, I could 
not observe any cell expressing Iba1 and AhR at the same time (Figure 4.3 a-a´´), 
indicating that microglia do not contain detectable levels of AhR protein in vivo.  
NG2+ oligodendrocyte progenitors also respond to brain injuries with morphological 
changes, increased proliferation and migration towards the injury (Simon et al., 2011), 
but also these cells were not AhR immunopositive (Figure 4.3 b-b´´).  
In double staining with GFAP, however, virtually all AhR+ cells proved to be reactive 
astrocytes (Figure 4.3 c-c´´). The response of astrocytes to brain injuries is well studied.  
We know that they become hypertrophic, upregulate GFAP and can reenter the cell cycle 
to form a compact astrocyte scar. A not yet characterized subset of astrocytes even 
acquires stem cell potential including multipotency and long-term self-renewal under 
neurosphere conditions in vitro.  
4.2 AhR activation with TCDD 
The evidence of AhR in reactive astrocytes naturally leads to the crucial question of my 
thesis: How does AhR signalling contribute to reactive gliosis, and to astrogliosis in 
particular?  
To address this question, I activated AhR with TCDD, a very potent and intensively 
studied AhR-agonist (Latchney et al., 2013; Poland et al., 1976), which was administered 
either systemically by gavage in three single doses throughout the duration of the 
experiment (Figure 4.4 a) or locally via direct injection into the stab wound at 3 dpi 
(Figure 4.4 b). The exact experimental procedure is described in chapter 3.1.3 / 3.1.4. 
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Figure 4.4 
 
 
Figure 4.4 Schedule of systemic (a) and local (b) TCDD treatment. For systemic 
treatment, mice were gavaged 3 times (0 dpi, 2 dpi and 4 dpi) with TCDD diluted in corn 
oil or with the vehicle only. BrdU in the drinking water labelled proliferating cells from 1 
dpi until perfusion at 5 dpi (a). Local treatment includes direct injection of TCDD into 
the stab wound at 3 dpi and subsequent BrdU administration in the drinking water. 
Here animals were also perfused at 5 dpi (b). 
 
4.2.1 Efficiency confirmation of TCDD treatment in AhR activation 
I first validated the effectiveness of AhR activation. In an inactive state a complex of 
proteins, including HSP90, restrains the receptor in the cytoplasm. After binding a 
ligand, AhR dissociates from the HSP90-complex and subsequently translocates into the 
nucleus where it heterodimerizes with AhR nuclear translocator (ARNT) to act as a 
transcription factor (see introduction; Figure 4.5). Therefore the localization of AhR in 
reactive astrocytes at 5 dpi can be used to monitor its activity. The nuclear localization 
displays the biologically active state, while a cytoplasmic localization represents the 
inactive state.  
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Figure 4.5 
 
Figure 4.5 Simplified scheme of AhR activation. Note, that the inactive receptor is 
restrained in the cytoplasm and only binding of a ligand can release AhR to translocate 
into the nucleus. 
 
Following systemic or local TCDD-treatment, I could indeed observe numerous reactive 
astrocytes with nuclear AhR (Figure 4.6 b-b´´´) whereas in absence of TCDD AhR was 
merely present in the cytoplasm and, thus, inactive in terms of the canonical AhR 
signalling pathway (Figure 4.6 a-a´´´).  
Orthogonal projections of confocal images depict precisely the intracellular distribution 
of AhR immunoreactivity in absence (Figure 4.6 c) and presence of TCDD (Figure 4.6 
d). Under control conditions AhR was scattered all over the cytoplasm, but triggered by 
TCDD, AhR accumulated in the perinuclear region and translocated into the nucleus. 
Due to the above-mentioned properties of AhR as a ligand dependent transcription 
factor, these findings provide evidence for the effectiveness of local and systemic TCDD 
treatment. 
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Figure 4.6
 
Figure 4.6 AhR activation by systemic TCDD administration. At 5 dpi, single plane 
confocal images of reactive astrocytes stained against GFAP and AhR show exclusively 
cytoplasmic AhR (yellow arrows) in absence of a ligand (a-a´´´) while in presence of 
TCDD, AhR (consistent with the biologically active state) could also be traced in the 
nucleus (white arrows) (b-b´´´). Orthogonal projections of confocal images additionally 
demonstrate the cytoplasmic localization of AhR in absence of a ligand (c) and its 
undisputable nuclear localization as a result of TCDD treatment (d). Similar effects were 
observed 5 dpi after local TCDD administration (not shown).  
Sale bars: 10 µm 
 
Systemic TCDD treatment affects all organs including liver, where AhR is well-known to 
regulate xenobiotic-metabolizing cytochrome P450 enzymes. Expression levels of 
CYP1A1, a target gene of AhR and member of the P450 enzyme family (Conney, 1982; 
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Ko, Okino, Ma, & Whitlock, 1996), were quantified by the use of realtime PCR to verify 
the transcriptional activity of AhR. The protocol I used for systemic TCDD treatment 
increased the number of CYP1A1-RNA transcripts in liver tissue by the factor 10,293 
(relative expression levels: 1.00 ± 0.45 vs. 10,292.63 ± 2,134.51) (Figure 4.7), 
confirming the efficiency of TCDD as an AhR activator. 
 
Figure 4.7 
 
Figure 4.7 Expression level of CYP1A1 in liver evaluated by qPCR. The histogram 
depicts CYP1A1 mRNA-levels (relative to RLP13 mRNA-levels) in liver tissue, which 
were more than 10,000 fold higher in mice treated with TCDD than in mice treated with 
the vehicle only (1.00 ± 0.45 vs. 10,292.63 ± 2,134.51).  
Bars in the histogram represent mean ± S.E.M. Asterisks depict the significance levels 
(***= p ≤ 0.001) obtained by t-test; n = 3. 
 
4.2.2 Effects of AhR activation on reactive gliosis in vivo 
After efficiency of TCDD treatment was confirmed, I investigated the effects of AhR 
activation on reactive gliosis in vivo with special focus on proliferation of different glial 
cell types in an area of 600 x 600 µm around the stab wound. 
4.2.2.1 Effects of systemic TCDD administration on reactive gliosis in vivo 
For these experiments animals were treated according to the schedule for systemic 
TCDD treatment (Figure 4.4 a), hence, all quantifications describe the injury state 5 dpi 
at the height of astrocyte proliferation (Bardehle et al., 2013). 
Increased proliferation of glial cells is distinctive of reactive gliosis and addition of BrdU 
(an thymidine analogue that incorporates into newly synthesized DNA) to the drinking 
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water labelled precisely those cells that underwent S-phase during the time of 
application, while immunostaining against Ki67, a nuclear protein associated with 
cellular proliferation, detected cells that were still in the cell cycle at the time of 
perfusion. 
Analysis of 5 animals per experimental group indicated a reduction by more than one 
third in the total number of BrdU+ cells in mice treated with TCDD compared to mice 
treated with the vehicle only (0.123  0.0041 vs. 0.0817  0.0082 cells per µm3; n= 5, p 
=0.0032, t-test; Figure 4.8), while the number of Ki67+ cells did not differ significantly 
(0.0275  0.0025 vs. 0.0227  0.0013 cells per µm3; n=5, t-test; Figure 4.8). 
 
Figure 4.8 
Figure 4.8 Proliferating cells in the injured brain. Systemic TCDD treatment 
significantly reduced the number of BrdU+ cells, but not the number of Ki67+ cells in 
response to stab wound injury at 5 dpi.  
Bars in the histogram represent mean ± S.E.M. Asterisks depict the significance levels 
(**= p ≤ 0.01) obtained by t-test. Analysis was done 5 dpi; n = 5. 
 
This change in the amount of BrdU+ cells is mainly due to impaired proliferation of 
microglia and astrocytes. In vehicle controls I counted 0.0239  0.0025 reactive 
astrocytes per µm3 that incorporated BrdU. TCDD reduced this number significantly to 
0.0140  0.0010 cells (n=5, p = 0.0136, t-test). The same applies for reactive astrocytes 
that were still in the cell cycle at the point of perfusion. Ki67+ astrocytes dropped from 
0.0106  0.0004 cells per µm3 to 0.0062  0.0005 cells per µm3 (n=5, p = 0.0002, t-test) 
(Figure 4.9 c). 
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Figure 4.9 
 
 
Figure 4.9 Effects of systemic TCDD administration on astrocyte proliferation. 
Confocal images of the lesioned cortex depict cells immunoreactivity for GFAP, Ki67 and 
BrdU. TCDD (b) reduced the numbers of proliferating astrocytes by more than one third 
compared to vehicle controls at 5 dpi (a). Red arrows: BrdU+ astrocytes, green arrows: 
Ki67+ astrocytes.  
Bars in the histogram (c) represent mean ± S.E.M. Asterisks depict the significance levels 
(*= p ≤ 0.05; ***= p ≤ 0.001) obtained by t-test. Scale bars: 100 µm; Analysis was done 5 
dpi; n = 5; Dashed lines indicate the site of injury. 
 
When exposed to TCDD, microglia, which accounted for the biggest proportion of BrdU+ 
cells, were also hindered from its full proliferative capacity (Figure 4.10 c) and the 
number of BrdU+ microglia consequently dropped more than 25 % from 0.0594  
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0.0017 cells per µm3 in control conditions to 0.0429  0.0025 cells per µm3 (n=3, p = 
0.0073, t-test) in TCDD treated animals. 
 
Figure 4.10 
 
 
Figure 4.10 Effects of systemic TCDD administration on microglia proliferation. 
Confocal images of the lesioned cortex stained against Iba1 and BrdU. In vehicle controls 
(a) microglia appear more numerous and hypertrophic and display a higher 
proliferative rate than in TCDD-treated animals at 5 dpi (b).  
Bars in the histogram (c) represent mean ± S.E.M. Asterisks depict the significance levels 
(**= p ≤ 0.01) obtained by t-test. Scale bars: 100 µm; Analysis was done 5 dpi; n = 3; 
Dashed lines indicate the site of injury. 
 
The only glial cells whose proliferation remained unaffected were cells of the 
oligodendrocytic lineage. Systemic TCDD treatment lowered the number of BrdU+ 
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oligodendrocyte progenitor cells with 0.0271  0.0067 cells per µm3 instead of 0.0316  
0.0016 cells per µm3 only slightly and not significantly (Figure 4.11). 
 
Figure 4.11
 
 
Figure 4.11 Effects of systemic TCDD administration on proliferation of 
oligodendrocyte progenitor cells. 
Confocal images of the lesioned cortex stained against Olig2, NG2 and BrdU. TCDD 
treatment did not restrict proliferation of oligodendrocyte progenitors.  
Bars in the histogram (c) represent mean ± S.E.M. Scale bars: 100 µm; Analysis was done 
5 dpi; n = 3; Dashed lines indicate the site of injury. 
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Regarding the absolute numbers of marker+ cells, there was no obvious change in the 
quantities of GFAP+ reactive astrocytes and Olig2+ oligodendrocytes. Only microglial 
cells decreased significantly in number (n=3, p = 0.0297, t-test) (Figure 4.12).  
 
Figure 4.12 
Figure 4.12 Numbers of different glial cells at the site of injury. The absolute 
numbers of astrocytes (GFAP) and oligodendrocyte progenitor cells (Olig2) did not 
change, while the number of microglia (Iba1) dropped significantly in response to 
systemic TCDD effects.  
Bars in the histogram represent mean ± S.E.M. Asterisks depict the significance levels 
(*= p ≤ 0.05) obtained by t-test. Analysis was done 5 dpi; n =5 for GFAP and n =3 for Iba1 
and Olig2. 
 
But AhR is only expressed in reactive astrocytes and not in microglia. Thus, similar 
effects of TCDD in both cell types surprise and raise the question if TCDD mediates the 
observed effects directly through AhR activation at the site of injury or rather through 
systemic changes that subsequently interfere with reactive glial cells. 
Interestingly the number of proliferating cells in the SVZ (labelled by addition of BrdU to 
the drinking water for 4 days), where AhR is not expressed, was also significantly 
reduced upon systemic TCDD treatment (0.0314  0.0020 vs. 0.0461  0.0030 cells per 
µm2; n=5, p = 0.0045, t-test) (Figure 4.13). This rather suggests, that proliferation is 
affected due to indirect effects of systemic TCDD application (Table 4.1). 
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Figure 4.13 
 
Figure 4.13 Effects of systemic TCDD administration on proliferation in the SEZ. 
Confocal images of the lesioned cortex stained against BrdU. TCDD had an anti-
proliferative effect on progenitor cells in the SEZ.  
Bars in the histogram (c) represent mean ± S.E.M. Asterisks depict the significance levels 
(**= p ≤ 0.01) obtained by t-test. Scale bars: 100 µm; Analysis was done after 4 days of 
BrdU infusion; n = 5. RMS = rostral migratory stream. 
 
Table 4.1 
Cell type 
Changed proliferation upon 
systemic  TCDD application 
AhR expression 
Astrocytes Yes Yes 
Microglia Yes No✖ 
Oligodendrocyte 
progenitor cells No✖ No✖ 
SEZ progenitors Yes No✖ 
Table 4.1 AhR expression and TCDD-induced changes in proliferation of different 
glial cell types. 
 
Since newly proliferating astrocytes shield vital neuronal tissue against inflammatory 
and cytotoxic effects in the lesion core (Bush et al., 1999), we should make sure that 
neurons do not suffer any damage by TCDD-induced inhibition of proliferation. 
Concerning this issue, I counted the number of NeuN expressing neurons in the 
isocortex immediately adjacent to the stab wound, but I did not detect a significant 
change in the number of NeuN+ cells (0.0585  0.0160 cells per µm3 in control 
conditions vs. 0.0480  0.0039 cells per µm3 in TCDD treated animals) (Figure 4.15) 
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Figure 4.14 
Figure 4.14 Numbers of NeuN+ cells at the site of Injury. Absolute numbers of NeuN+ 
cells (neurons) at the site of injury did not change upon systemic TCDD treatment.  
Bars in the histogram represent mean ± S.E.M; Analysis was done 5 dpi; n = 3.  
 
4.2.2.2 Effects of local TCDD administration on reactive gliosis in vivo 
To avoid systemic side effects of TCDD and to investigate the immediate function of AhR 
in reactive astrocytes, I changed the experimanetal approach towards local TCDD 
application (Figure 4.4 b), by directly injecting TCDD into the stab wound 3 dpi and 
BrdU-labelling of proliferating cells from the point of injection until perfusion 5 dpi. In 
contrast to oral treatment, cortical TCDD injection did not interfere with proliferation in 
the SEZ (Figure 4.15), supporting the assumption of a locally restricted TCDD effect.  
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Figure 4.15  
 
Figure 4.15 Effects of local TCDD administration on proliferation in the SEZ.  
Confocal images of the lesioned cortex stained against BrdU. Cortical TCDD injection did 
not interfere with proliferation of progenitor cells in the SEZ.  
Bars in the histogram (c) represent mean ± S.E.M. Scale bars: 100 µm; Analysis was done 
after 2 days of BrdU infusion; n = 3. RMS = rostral migratory stream. 
 
When administered locally, TCDD did not change the total numbers of BrdU+ cells and 
Ki67+ cells in the lesioned cortex. Quantification of proliferating cells gave 0.0091  
0.0016 Ki67+ cells and 0.0185  0.0036 BrdU+ cells per µm3 in vehicle controls and 
0.0102  0.0013 Ki67+ cells and 0.0254  0.0028 BrdU+ cells per µm3 in their TCDD-
treated siblings (Figure 4.16).  
 
Figure 4.16 
Figure 4.16 Proliferating cells in the injured cortex. Local TCDD treatment neither 
changed the number of BrdU+ cells, nor the number of Ki67+ cells at the site of injury 
significantly.  
Bars in the histogram represent mean ± S.E.M. Analysis was done 5 dpi; n = 5. 
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Bearing in mind that systemic TCDD deprived proliferation of reactive astrocytes, I was 
surprised to see that local TCDD evoked the exact opposite effect. Injection of TCDD at 
the site of injury doubled the number of BrdU+/GFAP+ cells from 0.0040  0.0005 cells 
per µm3 to 0.0081  0.0002 cells per µm3 (n=5, p = 0.0003, t-test). The number of 
Ki67+/GFAP+ cells rose equally from 0.0023  0.0001 cells per µm3 to 0.0036  0.0003 
cells per µm3  (n=5, p = 0.0106, t-test) (Figure 4.17).  
 
Figure 4.17 
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Figure 4.17 Effects of local TCDD administration on proliferation of astrocytes. 
Confocal images of the lesioned cortex stained against GFAP, Ki67 and BrdU. TCDD (b) 
doubled the numbers of BrdU+ astrocytes compared to vehicle controls (a) and also 
increased the numbers of Ki67+ astrocytes. Red arrows: BrdU+ astrocytes, green 
arrows: Ki67+ astrocytes.  
Bars in the histogram (c) represent mean ± S.E.M. Asterisks depict the significance levels 
(*= p ≤ 0.05; ***= p ≤ 0.001) obtained by t-test. Scale bars: 100 µm; Analysis was done 5 
dpi; n = 5; Dashed lines indicate the site of injury. 
 
Reactive gliosis is a complex process, which requires interaction of different cell types. 
Especially astrocytes and microglia are reported to interact by reciprocal activation and 
exchange of cytokines (Gao et al., 2013). Therefore it is worth examining the impact of 
AhR-induced changes in astrocytes on other glial cells, although local injection of TCDD 
avoided systemic side effects and although microglia and oligodendrocyte progenitor 
cells did not express AhR. 
At 5 dpi I counted 0.0089  0.0018 Iba1+/BrdU+ cells per µm3 under control conditions 
and 0.0094  0.0024 Iba1+/BrdU+ cells per µm3 under TCDD treatment, what does not 
describe a significant difference between both groups (Figure 4.18 a-a´´). The same 
findings apply for the proliferation of cells from the oligodendrocytic lineage. 0.0064  
0.0009 Olig2+/BrdU+ cells per µm3 in vehicle controls compare with 0.0063  0.0008 
Olig2+/BrdU+ cells per µm3 in TCDD-treated animals (Figure 4.18 b-b´´).   
 
Figure 4.18 
 
 
 57 
 
 
 
Figure 4.18 No effects of local TCDD administration on proliferation of microglia 
and oligodendrocyte progenitors. 
Confocal images of the lesioned cortex stained against Iba1 and BrdU (a, a´) or Olig2, 
NG2 and BrdU (b, b´) Morphology and amount of Iba1+/BrdU+ cells appears similar in 
vehicle controls (a) and in TCDD-treated animals (a´). Proliferation of oligodendrocyte 
progenitors also did not change under the influence of locally injected TCDD (b´).  
Bars in the histogram (a´´, b´´) represent mean ± S.E.M. Scale bars: 100 µm; Analysis was 
done 5 dpi; n = 3; Dashed lines indicate the site of injury. 
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In conclusion we can say, that local TCDD treatment acted specifically on astrocytes and 
allowed to study the pure effects of AhR activation in reactive astrocytes without 
interference of systemic side effects that would alter neurogenesis in the subependymal 
zone or proliferation of microglia and oligodendrocytes, as systemic TCDD-treatment 
did (Table 4.2).  
 
Table 4.2 
Cell type 
Changed proliferation upon local 
TCDD application 
AhR expression 
Astrocytes Yes✔ Yes✔ 
Microglia  No✖ No✖ 
Oligodendrocyte 
progenitor cells  No✖ No✖ 
SEZ progenitors No✖ No✖ 
Table 4.2 AhR expression and TCDD-induced changes in proliferation of different 
glial cell types. 
 
Especially when TCDD is directly injected into the brain, it is essential to notice that the 
absolute numbers of glial cells remained stable (Figure 4.19). With 0.0799  0.0082 
cells per µm3 in control conditions vs. 0.0728  0.0036 cells per µm3 in TCDD treated 
animals, the numbers of NeuN+ neurons were also unaffected (Figure 4.20). 
 
Figure 4.19 
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Figure 4.19 Numbers of different glial cells at the site of injury. Despite adjacent 
TCDD injection, the absolute numbers of astrocytes (GFAP), microglia (Iba1) and 
oligodendrocytes (Olig2) remained completely stable.  
Bars in the histogram represent mean ± S.E.M. Analysis was done 5 dpi; n = 5 for GFAP 
and n = 3 for Iba1 and Olig2.  
 
Figure 4.20 
Figure 4.20 Numbers of NeuN+ cells at the site of injury. The absolute numbers of 
NeuN+ cells (neurons) at the site of injury did not change upon local TCDD treatment.  
Bars in the histogram represent mean ± S.E.M; Analysis was done 5 dpi; n = 3.  
 
4.2.3 Effects of AhR activation on Stem Cell Properties In Vitro 
Immunohistochemistry showed that locally injected TCDD and subsequent AhR 
activation stimulates proliferation of reactive astrocytes. Reentering the cell cycle in 
order to proliferate requires mature astrocytes to dedifferentiate, what means that 
reactive astrocytes regain some features of glia in earlier developmental stages. 
Dedifferentiation confers reactive astrocytes with stem cell properties in vitro and 
causes expression of nestin, vimentin and tenascin-C in vivo.  
These markers of immature glia are upregulated simultaneously with AhR; AhR plays a 
role in stem cells outside the brain, e.g. in the haematopoietic system (Boitano et al., 
2010); and regulates embryonic stem cell differentiation (Gohlke, Stockton, Sieber, 
Foley, & Portier, 2009; Wang et al., 2013). This necessitates that we investigate whether 
AhR activation also supports the transition of mature astrocytes to immature 
progenitors with stem cell properties. 
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The neurosphere assay provides a tool to identify and quantify cells that form self-
renewing and multipotent neurospheres in vitro and, hence, feature both hallmarks of 
stem cells: the ability to self-renew and the ability to differentiate into multiple cell 
types (Chapter 3.3). 
 
Figure 4.21 
 
Figure 4.21 Scheme of the neurosphere assay. To address TCDD-induced changes in 
stem cell properties of reactive astrocytes, cells of the injured brain tissue were isolated 
at 5 dpi and plated in EGF-/FGF-containing neurosphere medium. Some of these cells 
formed neurospheres that were afterwards either differentiated to verify their 
multipotency or dissociated and replated to prove their self-renewing capacity.  
 
4.2.3.1 Effects of local TCDD administration 
For the following experiments I injected TCDD or the vehicle 3 dpi into the lesion site 
and isolated cells from the injured cortex 2 days later (Figure 4.22 a). After 14 days of 
proliferation under neurosphere conditions, I could not detect any differences in the 
ability to from spheres. Cells obtained either from control animals (Figure 4.22 b) or 
TCDD-injected animals (Figure 4.22 b´) gave rise to a comparable number of spheres: 
i.e. 5.00  0.58 spheres per 10,000 plated cells in controls and 6.33  0.83 spheres per 
10,000 plated cells upon TCDD (Figure 4.22 c). 
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Figure 4.22 
 
Figure 4.22 Effects of local AhR activation on injury-induced sphere formation in 
vitro. Scheme of local TCDD treatment (a). AhR activation by direct injection of TCDD 3 
dpi was not sufficient to support sphere formation. After proliferation for 14 days in 
neurosphere medium neither number nor size of spheres appeared different. Brightfield 
images of primary neurospheres depict these observations (b, b´).  
Bars in the histogram (c) represent mean ± S.E.M.; n = 3. 
 
4.2.3.2 Effects of systemic TCDD administration 
Local AhR activation did not affect sphere formation. Systemic AhR activation (Figure 
4.23 a), however, had a clear and unexpected effect. Although systemic TCDD treatment 
depleted the number of proliferating astrocytes in the injured cortex, it more than 
doubled the number of cells that kept proliferating under neurosphere conditions. 
Instead of 7.53  0.052 cells per 10,000 plated cells, 16.47  1.03 cells per 10,000 plated 
cells were able to form a primary neurosphere (n=3, p = 0.0001, t-test) within 14 days in 
culture (Figure 4.23 c). 
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Figure 4.23 
 
Figure 4.23 Effects of systemic AhR activation on injury-induced sphere formation 
in vitro. Scheme of systemic TCDD treatment (a). AhR activation by systemic TCDD 
application doubled the number of primary spheres (c). Brightfield images show 
representative primary neurospheres (b, b´).  
Bars in the histogram (c) represent mean ± S.E.M.; n = 3. 
 
But not only stem cells give rise to spheres in the neurosphere assay. Also transient 
amplifying cells might do so. Thus, stem cell properties of these spheres needed to be 
tested.  
Differentiation on adhesive substrate in absence of mitogens reveals the potential of the 
cell that gave rise to a primary neurosphere. In order to be called multipotent, a cell 
must be able to generate cells from different lineages. In the case of neuronal stem cells 
these are neurons, oligodendrocytes and astrocytes. Immunohistochemic stainings after 
7 days of differentiation (Figure 4.24 a, a´) showed that about one third of all spheres, 
no matter if derived from TCDD or vehicle treated animals, fulfilled this criterion 
(Figure 4.24 b). 
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Figure 4.24 
Figure 4.24 Multipotency of primary cortical neurospheres. Increased formation of 
primary neurospheres in response to systemic TCDD treatment did not affect their 
potential. In both conditions about one third of the spheres gave rise to neurons, 
astrocytes and oligodendrocytes (b), a feature that requires multipotency. 
Representatives of these multipotent spheres are pictured in confocal images (a, a´). 
Bars in the histogram (c) represent mean ± S.E.M.; n =3 for SW + TCDD, n=2 for SW only; 
Scale bars: 20 µm. 
 
The second hallmark of stem cells is their ability to self-renew. If neurospheres that 
originate from stem cells are dissociated, re-plated as a single cell suspension and 
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afterwards cultured under neurosphere conditions for seven days, they will always give 
rise to new spheres (Figure 4.21). 
Cells from systemic TCDD-treated animals initially produced twice as many primary 
neurospheres as did cells from vehicle-treated animals. But the following generations of 
spheres even produced many times more. After each passage, cells that originate from 
animals treated with TCDD gave rise to at least 7.69 times more neurospheres than did 
control cells (Tab 7.3), and it was not only the number of neurospheres, but also their 
size that was impressive (Figure 4.25). This increase in proliferation and self-renewing 
capacity lasted for at least three passages  and this means for at least 5 weeks  
although the only thing that separated the two cultures was the previous TCDD 
administration in vivo.  
 
Figure 4.25 
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Figure 4.25 Self-renewing capacity of primary cortical neurospheres.  
Systemic TCDD treatment increased proliferation and self-renewing capacity 
permanently. Spheres derived from TCDD treated animals were superior in size (a, a´ - 
c, c´) and number (d). 
Bars in the histogram (d) represent mean ± S.E.M.; n = 3; p-value was obtained by t-test.  
Scale bars: 200 µm.  
 
Table 4.3 
 
Number of spheres per 10,000 plated cells 
Vehicle                        TCDD p-value Fold change 
Primary spheres 7.53  0.52 16.47  1.02 0.0001 2.19 
Secondary spheres 9.17  2.19 89.50  24.62 0.0813 9.76 
Tertiary spheres 5.67  0.88 43.56  8.37 0.0441 7.69 
Quaternary spheres 10.33  1.45 124.22  12.95 0.0119 12.02 
Table 4.3 Sphere formation and self-renewing capacity of cells isolated from the 
injured cerebral cortex after systemic TCDD treatment.  
Data is shown as mean ± S.E.M.; p-value was obtained by t-test.  
 
When the neurosphere assay was performed with cells from the intact cortex or the SEZ, 
no significant changes in numbers or morphology of formed spheres were detectable. 
Cells isolated from the intact cortex contralateral to the SW gave rise to hardly any 
neurospheres. In vehicle controls these were 0.25  0.25 spheres per 10,000 plated cells 
and 1.5  0.50 spheres per 10,000 plated cells after systemic TCDD treatment. In both 
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conditions I was not able to passage these spheres, which questions, of course, their 
status as neurospheres.  
 
Figure 4.26 
Figure 4.26 Effects of systemic AhR activation on sphere formation of the intact 
cortex. Without previous injury, systemic AhR activation did not change sphere 
formation.  
Bars in the histogram (a, b) represent mean ± S.E.M.; n = 4 
 
As expected from a neuronal stem cell niche, the SEZ generated a large number of 
neurospheres, but with 173.14 ± 59.40 spheres per 10,000 plated cells in controls and 
187.89 ± 58.45 spheres per 10,000 plated cells upon TCDD treatment, the numbers of 
neurospheres did not change (Figure7.27 a). Sphere size was also not significantly 
different (Figure7.27 b).  
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Figure 4.27 
 
Figure 4.27 Sphere formation of the SEZ in response to systemic TCDD treatment. 
Systemic AhR activation did not affect neurosphere formation in the subependymal 
zone. Numbers (a) and size (b) of spheres remained unaltered. Representative 
brightfield images show primary SEZ neurospheres from controls or TCDD treated 
animals after 7 days in culture (c, c´). 
Bars in the histogram (a, b) represent mean ± S.E.M.; n = 6. 
 
Table 4.4 
Brain region 
   Increased stem cell properties 
TCDD local              TCDD Systemic 
AhR expression 
Cortex intact - No ✖ No✖ 
Cortex injured No✖ Yes✔ Yes✔ 
SEZ - No✖ No✖ 
Table 4.4 AhR expression and TCDD-induced changes in the stem cells content of 
different brain regions.  
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4.3 Proteomics 
My previous experiments basically put forth three findings: (Table 4.4) 
1.) Oral TCDD treatment was only able to increase sphere formation if the donor 
tissue expressed AhR. 
2.) Systemic TCDD treatment, but not local TCDD treatment, was sufficient to 
increase sphere formation after stab wound injury.  
3.) The major difference between these two methods of AhR activation in vivo was 
the extent of glial cell proliferation at the site of injury.  
To further address the factors that enrich stem cells properties of reactive astrocytes 
upon systemic TCDD treatment, I submitted samples of the intact and injured cortex (5 
dpi) with and without previous oral TCDD treatment to proteome analysis.2 Analysis 
was performed on whole tissue samples to cover possible changes in reactive astrocytes 
as well as in their environment. Comparison of TCDD effects in the intact and the injured 
cortex was intended to distinguish between injury-related effects of TCDD and systemic 
effects that are independent from injury and cortical AhR expression.  
Systemic side effects of TCDD treatment, which are not linked to AhR activation in the 
analysed cortical tissue and do not promote dedifferentiation of reactive astrocytes, 
might be present in both conditions: In the intact cortex and in the lesioned cortex. But 
TCDD-induced changes in protein expression that support the formation of 
neurospheres should only be present in the injured cortex but not in the intact cortex. 
Label-free-LC-MSMS-based proteomic identified 2704 proteins. The normalized protein 
intensities were tested for differential expression in TCDD and vehicle treated mice and 
the resulting p-values were plotted against the ratios (TCDD / vehicle) in vulcano plots 
(Figure 4.28).  
 
 
 
 
 
 
                                                        
2 Collaboration with Dr. Stefanie Hauck, Research Unit Protein Science, Helmholtz 
Zentrum München  
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Figure 4.28 
 
Figure 4.28 Volcano plots showing p- values (-log10) and protein ratio (log2) of 
TCDD-treated vs. Vehicle-treated animals. Dots above the horizontal line represent 
significantly enriched/depleted fractions in the intact cortex (a) and in the injured 
cortex (b) (p < 0.05). Dots on right sides represent proteins that are upregulated upon 
TCDD treatment and dots on left sides represent downregulated proteins. Significantly 
upregulated proteins are depicted in blue, significantly downregulated proteins are 
depicted in red.  
 
In the injured cortex (Figure 4.28 b) we identified 95 proteins whose expression levels 
were significantly changed upon TCDD treatment. 54 were upregulated and another 41 
were downregulated (Table 4.5). TCDD treatment without injury resulted with 39 
upregulated proteins and 53 downregulated proteins in altogether 92 differentially 
expressed proteins (Figure 4.28 a). Remarkably, only 2 proteins changed concordantly 
in the injured and the intact cortex (Table 4.5) what points again to different effects of 
TCDD in both conditions.  
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Table 4.5 
 
Table 4.5 TCDD-induced changes in protein expression of the intact and injured 
cortex. 
 
If we have a look at the significantly differently regulated proteins in the injured cortex, 
we can detect quite some interesting candidates, which are affected by AhR signalling or 
play a role in reactive gliosis. Slc7a2 for example is supposed to play a role in the 
classical or alternative activation of macrophages via its role in arginine transport 
(Yeramian et al., 2006). Otub1, whose expression rate was significantly lower upon 
TCDD, destabilizes the active ubiquitin E3 ligase GRAIL, which is crucial in the induction 
of CD4+ T-cell anergy (Soares et al., 2004). Akt/mTOR signalling controls stem cell 
pluripotency and differentiation (Yu & Cui, 2016). Since Akt is modulated by AhR 
signalling (Wu, Zhang, Hoagland, & Swanson, 2007; Xu et al., 2014) and since mTOR 
expression was significantly higher in samples of TCDD treated animals, this is one 
mechanism how AhR signalling might affect proliferation and fate of reactive astrocytes. 
With the assistance of „The Database for Annotation, Visualization and Integrated 
Discovery (DAVID) v6.7” (Huang da, Sherman, & Lempicki, 2009), I tested all proteins 
that were upregulated upon TCDD treatment and all proteins that were downregulated 
upon TCDD treatment for enriched Gene Ontology (GO) terms, whereby the list of all 
identified proteins served as background. All significantly enriched GO terms (modified 
Fischer Exact Test: p-value ≤ 0.05) with at least 3 query genes are listed in Table 4.6 and 
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Table 4.7.  
 
Table 4.6 
GO term p-value 
Fold 
enrich-
ment 
Proteins 
Biological processes  
Cellular component 
assembly 
0.0069 3.8 
 
CORO1C, HIST1H2BC, GSN, BAIAP2, PAFAH1B1, PAK1, 
TUBB1 
 
Cellular component 
biogenesis 
0.0084 3.7 
 
CORO1C, HIST1H2BC, GSN, BAIAP2, PAFAH1B1, PAK1, 
TUBB1 
 
Cellular components  
Non-membrane-
bounded organelle 
6.64E-04 2.6 
 
TCP1, HIST1H2BC, TWF2, SRCIN1, KIF5B, WASF1, GM9396, 
RPS5, CORO1C, CORO2B, GSN, PAFAH1B1, TUBB1, UBXN6 
 
Intracellular non-
membrane-bounded 
organelle 
6.64E-04 2.6 
 
TCP1, HIST1H2BC, TWF2, SRCIN1, KIF5B, WASF1, GM9396, 
RPS5, CORO1C, CORO2B, GSN, PAFAH1B1, TUBB1, UBXN6 
 
Cytoskeleton 0.0012 3.1 
 
CORO1C, CORO2B, TCP1, TWF2, KIF5B, SRCIN1, GSN, 
WASF1, PAFAH1B1, UBXN6, TUBB1 
 
Cell leading edge 0.0237 6.1 
 
GSN, WASF1, BAIAP2, PAFAH1B1 
 
Microtubule 
cytoskeleton 
0.0278 4.1 
 
TCP1, KIF5B, PAFAH1B1, UBXN6, TUBB1 
 
Centrosome 0.0369 9.4 
 
TCP1, PAFAH1B1, UBXN6 
 
Microtubule 
organizing centre 
0.0433 8.6 
 
TCP1, PAFAH1B1, UBXN6 
 
Molecular function  
Cytoskeletal protein 
binding 
0.0022 4.1 
 
CORO1C, CORO2B, TWF2, KIF5B, GSN, WASF1, BAIAP2, 
PAFAH1B1 
 
Actin binding 0.04114 3.7 
 
CORO1C, CORO2B, TWF2, GSN, WASF1 
 
Table 4.6 Go terms enriched in proteins that were significantly downregulated 
upon TCDD treatment in the injured cortex. P-value of enriched GO terms was 
obtained by Modified Fisher's Exact Test. 
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Table 4.7 
GO term p-value 
Fold 
enrich-
ment 
Proteins 
Biological processes  
Transport 0.0101 1.6 
 
SYT1, COPA, SLC8A1, SYT2, SYT12, ATP1A3, SLC7A10, 
SFXN1, ARF6, ABCG3, TMED9, STXBP5L, RTN3, SLC32A1, 
TMED4, SLC25A25, SLC7A2, SLC30A1, SLC25A23, SEC22B, 
NDUFS2, RAB21 
Establishment of 
localization 
0.0106 1.6 
 
SYT1, COPA, SLC8A1, SYT2, SYT12, ATP1A3, SLC7A10, 
SFXN1, ARF6, ABCG3, TMED9, STXBP5L, RTN3, 
SLC32A1, TMED4, SLC25A25, SLC7A2, SLC30A1, 
SLC25A23, SEC22B, NDUFS2, RAB21 
Localization 0.0235 1.5 
 
SYT1, COPA, SLC8A1, SYT2, SYT12, ATP1A3, SLC7A10, 
SFXN1, ARF6, ABCG3, TMED9, STXBP5L, RTN3, 
SLC32A1, TMED4, SLC25A25, SLC7A2, SLC30A1, 
SLC25A23, SEC22B, NDUFS2, RAB21 
Cellular components  
Integral to membrane 1.60E-10 2.5 
 
SYT1, COPA, SLC8A1, SYT2, SYT12, ATP1A3, SLC7A10, 
SFXN1, ARF6, ABCG3, TMED9, STXBP5L, RTN3, SLC32A1, 
TMED4, SLC25A25, SLC7A2, SLC30A1, SLC25A23, SEC22B, 
NDUFS2, RAB21 
Intrinsic to 
membrane 
3.30E-10 2.4 
 
SYT1, COPA, SLC8A1, SYT2, SYT12, ATP1A3, SLC7A10, 
SFXN1, ARF6, ABCG3, TMED9, STXBP5L, RTN3, SLC32A1, 
TMED4, SLC25A25, SLC7A2, SLC30A1, SLC25A23, SEC22B, 
NDUFS2, RAB21 
Membrane part 5.20E-07 1.7 
 
SYT1, COPA, SLC8A1, SYT2, SYT12, ATP1A3, SLC7A10, 
SFXN1, ARF6, ABCG3, TMED9, STXBP5L, RTN3, SLC32A1, 
TMED4, SLC25A25, SLC7A2, SLC30A1, SLC25A23, SEC22B, 
NDUFS2, RAB21 
Membrane 4.20E-06 1.6 
 
SYT1, COPA, SLC8A1, SYT2, SYT12, ATP1A3, SLC7A10, 
SFXN1, ARF6, ABCG3, TMED9, STXBP5L, RTN3, SLC32A1, 
TMED4, SLC25A25, SLC7A2, SLC30A1, SLC25A23, SEC22B, 
NDUFS2, RAB21 
Endoplasmic 
reticulum 
0.0051 2.7 
 
SYT1, COPA, SLC8A1, SYT2, SYT12, ATP1A3, SLC7A10, 
SFXN1, ARF6, ABCG3, TMED9, STXBP5L, RTN3, SLC32A1, 
TMED4, SLC25A25, SLC7A2, SLC30A1, SLC25A23, SEC22B, 
NDUFS2, RAB21 
Plasma membrane 0.0112 1.7 
 
SYT1, COPA, SLC8A1, SYT2, SYT12, ATP1A3, SLC7A10, 
SFXN1, ARF6, ABCG3, TMED9, STXBP5L, RTN3, SLC32A1, 
TMED4, SLC25A25, SLC7A2, SLC30A1, SLC25A23, SEC22B, 
NDUFS2, RAB21 
Molecular function  
Transporter activity 0.0177 2.2 
 
SLC32A1, SYT1, SLC8A1, SLC30A1, SLC7A2, SYT2, SLC25A23, 
SYT12, ATP1A3, SLC7A10, SFXN1 
Transmembrane 
receptor activity 
0.02082 4.5 
 
EPHA4, GPR162, GABBR2, MOG, GPR37L1 
Table 4.7 Go terms enriched in proteins that were significantly upregulated upon 
TCDD treatment in the injured cortex. P-value of enriched GO terms was obtained by 
Modified Fisher's Exact Test. 
 
GO term analysis yielded several significantly (p ≤ 0.05, Modified Fisher's Exact Test) 
downregulated terms (Table 4.6). Among them are Cellular component biogenesis and 
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assembly, Cytoskeleton, Cell leading edge, Microtubule cytoskeleton, Centrosome and 
Microtubule organizing centre, reflecting the TCDD-induced impairment of proliferation 
after stab wound injury. The significantly overrepresented GO terms are mostly related 
to membrane proteins including proteins with transporter or receptor activity (Table 
4.7), reflecting differences in intracellular signalling pathways.  
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5 Discussion 
The absence of AhR in the intact cortex and the massive upregulation in response to TBI 
demonstrates that TBI triggers AhR expression and that AhR signalling is involved in the 
subsequent process of wound healing.  
Immunohistochemical stainings identified astrocytes as the only cell type expressing 
AhR and showed that AhR is expressed by all reactive astrocytes in a diameter up to 500 
µm around the injury site. The expression of AhR in reactive astrocytes occurred 
simultaneously to the upregulation of GFAP, the classical marker for reactive 
astrogliosis, and peaked at 3 dpi, right at the time when astrocytes start proliferating 
and expressing markers of immature astrocytes like Nestin, Vimentin and tenascin-C 
(Robel, Berninger, & Gotz, 2011). This implies that AhR is either mediator or part of 
these reactive changes in astrocytes. Reactive astrocytes regain features of glia present 
at earlier developmental stages and stem cell properties, at least in vitro. AhR regulates 
differentiation and self-renewal of numerous stem cell populations, such as in the 
hematopoietic (Boitano et al., 2010; Smith et al., 2013) and the lymphoid system (Li et 
al., 2011), in the CNS (Dever et al., 2016; Latchney et al., 2011) and in liver (Walisser, 
Glover, Pande, Liss, & Bradfield, 2005). Therefore, the expression of AhR in reactive 
astrocytes also suggests that AhR has a role in the process of astrocyte reactivation, 
dedifferentiation and proliferation.  
Consistent with previously published data (Latchney et al., 2013; Petersen et al., 2000), I 
found AhR expressing cells in the subgranular zone of the hippocampus, one of the two 
major brain regions where adult neurogenesis occurs. This emphasizes the role of AhR 
in the regulation of stem cell populations and confirms the reliability of my 
immunohistochemic stainings. But AhR was not detectable in the second neurogenic 
niche, the subependymal zone (SEZ) of the lateral ventricle. Thus, AhR seems to be 
involved in the proliferation and differentiation of various types of stem cells, including 
adult neuronal stem cells, but is not obligatory to this process.  
Without potentiation of AhR signalling by TCDD, I located AhR exclusively in the 
cytoplasm of astrocytes. This corresponds to the inactive state of AhR and it is curious, 
why AhR in reactive astrocytes is highly expressed but inactive. Either I missed the time 
of physiological AhR activity, or the concentration of nuclear AhR was below the 
detection rate of my immunohistochemic staining. It is also possible that AhR does not 
act via the canonical AhR signalling pathway, but crosstalks with other signalling 
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pathways like the EGFR, which does not demand a nuclear transport of AhR (Enan & 
Matsumura, 1995).  
The expression levels of AhR varied quite significantly among individual astrocytes. 
Some astrocytes express very high levels of AhR, comparable to cells in the subgranular 
zone of the hippocampus, whereas others show only slight AhR-stainings. As shown in 
co-stainings with BrdU and Ki67, this variability does not correlate with the proliferative 
stage of astrocytes. Although little is known about local differences of astrocytes, it is 
generally assumed that astrocytes are a heterogeneous group of cells (Anderson, Ao, & 
Sofroniew, 2014). The assumption of local heterogeneity among neighbouring 
astrocytes is supported by studies that report variable expression levels of different 
chemokines or cytokines (Hamby et al., 2012), the transcription activator Stat3 
(Herrmann et al., 2008) and transcription factors that are necessary for sonic hedgehog 
signalling (Garcia, Petrova, Eng, & Joyner, 2010). Stab wound lesions of the cerebral 
cortex evoked elective proliferation of juxtavascular astrocytes, which points towards 
a functional specialization among reactive astrocytes (Bardehle et al., 2013). Similarly, 
AhR signalling might also acts on particular subpopulations and functions of reactive 
astrocytes. 
5.1 Effects of AhR activation on reactive gliosis 
In order to study the role of the AhR pathway in reactive gliosis, I potentiated AhR 
signalling by either local or oral administration of the potent and intensively studied 
AhR agonist TCDD. Both, oral and local TCDD administration, changed proliferation rate 
of reactive astrocytes significantly and, most strikingly, oral TCDD treatment more than 
doubled sphere formation in the neurosphere assay. Differentiation of spheres showed 
comparable neurogenic potential of spheres from TCDD-treated and untreated animals. 
However, they differed clearly in terms of self-renewal and proliferation. While primary 
spheres form TCDD-treated animals appeared marginally smaller than spheres from 
vehicle treated controls, subsequent generations of spheres from TCDD-treated animals 
were much bigger and much more numerous than control spheres. These changes lasted 
for several generations of spheres although culture conditions were exactly the same. 
This indicates robust, TCDD-induced changes within the sphere forming cells that also 
affect following generations of sphere forming cells.  
The increase in neurosphere formation is a remarkable finding, especially since 
proliferation of reactive astrocytes in vivo was clearly impaired upon systemic TCDD 
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treatment. Until now, proliferation of astrocytes in vivo and sphere formation in vitro 
have always been regarded as two indicators of the same process: The differentiation of 
reactive astrocytes in response to brain injuries (Buffo et al., 2008; Sirko et al., 2013). 
Here on the contrary, decreased numbers of proliferating astrocytes were accompanied 
by increased generation of neurospheres. To my knowledge, this is the first time it is 
shown that proliferation and dedifferentiation do not necessarily go hand in hand and 
might depend on different mechanisms that are only effective in a distinct subtype of 
astrocytes. The inconsistent expression levels of AhR in neighbouring astrocytes support 
this hypothesis, although the correlation of AhR-expression with stem-cell properies still 
needs to be evaluated.  
Importantly, neuronal survival was not impaired by increased stem cell properties and 
reduced proliferation of astrocytes and other glial cells. The number of NeuN+ cells 
round the injury did not change upon TCDD treatment and systemic treatment with 
TCDD increased stem cell properties without boosting reactive gliosis, which is regarded 
to be causative for the failure of neuronal regeneration after injury. Therefore, AhR is a 
promising target in the search for regenerative therapies for all kind of diseases that are 
associated with a loss of functional neurons.  
Oral TCDD treatment generally reduced the number of proliferating cells in the stab-
wounded cortex and in the SEZ. Hence, it was not clear, weather the observed changes in 
reactive gliosis are due to a direct effect of AhR activation in reactive astrocytes of if they 
are rather due to systemic effects of TCDD. TCDD did not act specifically on AhR 
expressing astrocytes but reduced proliferation of all glial cells and of progenitor cells in 
the SEZ, which rather suggests a systemic effect of TCDD. But it is also known that 
different glial cells interact in response to brain injuries. Therefore, reduced 
proliferation of reactive astrocytes as a direct effect of AhR activation might also alter 
the proliferation rate of neighbouring glial cells. In the contralateral intact cortex, where 
AhR is not expressed, TCDD treatment did not increase sphere formation and in the SEZ, 
proliferation but not sphere formation was affected by systemic TCDD treatment. These 
findings rather suggest that the increase of sphere formation in the injured cortex is due 
to a direct effect of AhR at the site of injury whereas the reduced proliferation of all glial 
cell lines reflects systemic TCDD effects.  
AhR suppresses inflammatory responses (Huai et al., 2014; Rothhammer et al., 2018), 
induces a switch in T-cells from a stimulatory into a regulatory phenotype, the Treg-cells, 
and suppresses T cell-dependent immune reactions (Mascanfroni et al., 2015; Mohinta 
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et al., 2015; Quintana et al., 2008). The activation of AhR in liver cells induces the release 
of TGF-β, a cytokine that limits inflammation after brain injuries and attenuates 
microglial activation (Cekanaviciute, Dietrich, et al., 2014; Cekanaviciute, Fathali, et al., 
2014; Norden, Fenn, Dugan, & Godbout, 2014). Furthermore, astrocytic or microglial 
AhR activation by tryptophan metabolites limit CNS inflammation (Rothhammer et al., 
2018). But inflammation triggers tissue repair and wound healing (Martin & Leibovich, 
2005) and invasion of immune cells is necessary to evoke proliferation of astrocytes 
(Berger, Hiestand, Kindler-Baumann, Rudin, & Rausch, 2006). Thus, the reduced level of 
reactive gliosis might also mirror a suppressed immune response.  
In order to look into direct effects of AhR activation at the site of injury, I injected TCDD 
3 dpi directly into the stab-wounded cortex. Although the nuclear localization of AhR in 
the immunostainings proved the efficiency of both ways of AhR activation, the local and 
oral TCDD-administration, local treatment failed to increase sphere formation. But it 
specifically promoted proliferation of reactive astrocytes, the only AhR expressing cells 
in the injured cerebral cortex. Proliferation of other glial cell types at the site of injury 
and proliferation of progenitor cells in the SEZ was not affected, which argues for a 
direct effect of AhR activation in reactive astrocytes.  
5.2 Discrepancy between effects of local and oral TCDD treatment 
Following systemic TCDD treatment, I observed an increase in sphere formation 
specifically in the cortex, what rather suggests a direct effect of TCDD, but local TCDD 
administration failed to increase sphere formation. This can be attributed to a wrong 
time of administration or an ineffective dose of TCDD. In zebrafish, AhR was inactivated 
within 2 dpi. Permanent activation increased neuronal differentiation but depleted the 
number of proliferating progenitors. If we transfer these findings to mouse, we can 
hypothesize that the initial AhR signalling fosters dedifferentiation of reactive astrocytes 
and allows them, at least in vitro, to give raise to neurons. Afterwards, AhR signalling is 
reduced to promote proliferation of dedifferentiated astrocytes. This might also explain 
why we cannot detect AhR in the nucleus at 5 dpi. Injection of TCDD at 3 dpi might not 
be sufficient to keep AhR signalling at a high level until 5 dpi in order to increase sphere 
formation in the neurosphere assay or, if astrocytes are already primed towards their 
gliogenic fate, an injection at 3 dpi is too late to induce a more neurogenic fate by the 
potentiation of AhR signalling. 
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We should also consider, that systemic TCDD treatment did not only alter proliferation 
of astrocytes, but also the proliferation of each glial cell line. Reactive gliosis at the site of 
injury has got beneficial and detrimental effects. It helps to restore the BBB after TBI 
and protects still viable cells from further harm. But it also creates a gliogenic 
environment, which hinders neuronal regeneration and axonal regrowth. Thus, AhR 
activation alone might not be sufficient to increase stem cell properties of reactive 
astrocytes. Only if AhR activation occurs in a more permissive milieu with a lower 
degree of gliosis and less inflammation, it can increase stem cell properties of reactive 
astrocytes. The gliogenic environment of the cerebral cortex might not only hinder 
dedifferentiation of reactive astrocytes. It also keeps reactive, proliferating astrocytes 
within their lineage in vivo, whereas in vitro they are able to generate astrocytes, 
oligodendrocytes and neurons. Thus, it might be the combination of AhR activation, 
reduced inflammation and a lower degree of reactive gliosis at the site of injury that 
promotes stem cell properties.  
5.3 Proteomic 
We performed a proteome analysis to get a better understanding of the mechanisms by 
which systemic TCDD treatment favours neurosphere formation and stem cell 
properties at the site of injury. Subsequent GO term analysis of all downregulated 
proteins showed a significant increase of GO terms related to cell proliferation, which 
confirms the effects observed by immunostainings. Significantly upregulated upon TCDD 
treatment were mainly membrane proteins such as transmembrane receptors and 
transporters, which reflect differences in cell signalling and metabolism.  
In order to get an idea of whether the increase in neurosphere formation is due to 
systemic or local effects of the oral TCDD treatment, I examined the proteome data for 
proteins that are annotated to the GO-terms “immune system process”, “transforming 
growth factor beta receptor signalling pathway” and “tumour necrosis factor-mediated 
signalling pathway”, since these domains are known to be affected by systemic TCDD 
treatment and interfere with reactive gliosis and neuroinflammation (Berger et al., 
2006; Cekanaviciute, Dietrich, et al., 2014; Cekanaviciute, Fathali, et al., 2014; Cheon et 
al., 2007; Huai et al., 2014; Mohinta et al., 2015; Norden et al., 2014; Rier et al., 2001). 
Transforming growth factor beta and tumour necrosis factor alpha do not seem to cause 
the increase in stem cell properties, since none of the 18 identified proteins related to 
“transforming growth factor beta receptor signalling pathway” and none of the 25 
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identified proteins related to “tumor necrosis factor” or “tumor necrosis factor-mediated 
signalling pathway” differed significantly between TCDD treated animals and vehicle 
treated controls. I also found 236 proteins that are involved in “immune system 
processes” and 12 of them differed significantly between TCDD treated animals and 
vehicle treated controls. This resembles the general proportion of significantly different 
proteins (= 95/2704) and GO term analysis also did not show enrichment in terms 
related to the immune system. Most of these 12 proteins are not unique for the immune 
system, but play a general role in cellular metabolism, growth or microtubule-
dependent processes. 
Some of the differentially regulated proteins are quite interesting in context of reactive 
gliosis. Slc7a2 plays a role in the in classical or alternative activation of macrophages 
(Yeramian et al., 2006), Otub1 is crucial in the induction of CD4+ T-cell anergy (Soares et 
al., 2004) and Akt/mTOR signalling controls stem cell pluripotency and differentiation 
(Yu & Cui, 2016). Since Akt is modulated by AhR signalling (Wu et al., 2007; Xu et al., 
2014) and since Mtor expression was significantly higher in samples of TCDD treated 
animals, this is one possible mechanism how AhR signalling affects proliferation and fate 
of reactive astrocytes. But we should be careful not to overestimate the functional 
relevance of these proteins. We see only single proteins without their involvement in 
certain functions and pathways and in order to get a reliable readout, the differential 
expression of these proteins still has to be validated by western blot or real-time PCR.  
5.4 Outlook 
My work demonstrates that AhR signalling affects reactive astrogliosis. However, the 
exact mode of action remains to be investigated. Oral TCDD treatment increased sphere 
formation in the neurosphere assay and it will be important to find out, which TCDD- 
induced changes really promote stem cell properties of reactive astrocytes. It should be 
verified, whether AhR activation in combination with a lower degree of gliosis can help 
to regenerate neurons from reactive astrocytes after TBI, similar to ependymoglia in the 
injured zebrafish telencephalon. At 5 dpi I could not observe any DCX (marker for 
immature neurons) positive cell at the site of injury, but this time period might be too 
short and should be extended to draw a definitive conclusion.  
It is known that reactive astrocytes divide only once in response to TBIs before they 
reenter the post-mitotic state. In brain section of TCDD treated animals, however, 
several astrocytes were clustered in groups of at least 3. Clonal analysis techniques will 
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help to see, weather AhR activation is sufficient to keep astrocytes in their proliferative 
state, so that they divide more than once.  
The most important task will be to examine the physiological function of AhR in reactive 
gliosis. Since the receptor affinity differs between TCDD and endogenous ligands and 
since ligand-dependent effects have been reported in other organs, activation studies 
are not appropriate for this aim. Furthermore, immunohistochemical stainings showed 
only cytoplasmic AhR in absence of the external ligand TCDD, which means that AhR 
might act via non-canonical pathways such as crosstalk with the EGFR. These 
restrictions ask for experimental settings in which AhR can be selectively blocked in 
reactive astrocytes. Conditional knockout mice with a floxed AhR-gene, which express 
CreER(T2) recombinase under the promoter of the astrocyte-specific glutamate 
transporter (GLAST) or GFAP, are a promising approach to investigate the physiological 
functions of AhR in reactive gliosis and to separate indirect, systemic effects of AhR 
activation from effects of AhR activation directly in reactive astrocytes. 
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